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Introduction
Case 
A 74-year-old woman, living in an iodine deficient area, visits the general practitioner because 
of persistent fatigue. She has a medical history of dyslipidemia. One year ago, her thyroid 
function was tested because of fatigue, weight gain and cold intolerance. At that time, blood 
results showed a thyroid stimulating hormone (TSH) level of 3.8 mIU/L (reference range 0.4-
4.0 mIU/L), a free thyroxine (FT
4
) level of 10.2 pmol/L (reference range 8-22 pmol/L) and the 
presence of thyroid peroxidase antibodies. No other physical illness was revealed that might 
have caused the symptoms. Thyroid hormone substitution therapy was started. The symptoms 
of weight gain and cold intolerance improved slightly. However, despite the treatment 
with levothyroxine, she is still complaining of fatigue. Her current TSH level (while using 
levothyroxine 50 micrograms once daily) is 2.6 mIU/L.   
This case raises several questions. Does this woman have thyroid dysfunction? Is the decision 
of the general practitioner to prescribe thyroid hormone replacement therapy a year ago 
justifiable? Would the age of the patient who presented with a TSH level of 3.8 mIU/L have 
influenced the decision on whether to start with replacement therapy or not? Should the 
clinician take other characteristics, such as the ethnicity or the (presumed) iodine status of the 
patient and her population background into account for the interpretation of the laboratory 
results and the decision on whether to initiate the replacement therapy? And once decided to 
start with replacement therapy, what should be the target level of TSH during treatment? Is 
the optimal target level of TSH the same for all patients? What is the cause of the persistent 
fatigue, despite adequate thyroid hormone replacement?
Clinicians, treating patients with thyroid dysfunction, have to deal with these issues frequently. 
Overt thyroid dysfunction is clearly associated with symptoms, morbidity and mortality. 
However, the consequences of small variations in thyroid function on symptoms, morbidity and 
mortality and the definition of normal thyroid function (i.e. the reference range of serum TSH) 
are still under debate. Currently, the reference range of serum TSH is based on the 2.5th and 
97.5th percentile of the population. A more logical approach would be to base the reference 
limits on clinical outcomes. Therefore, studies investigating associations between thyroid 
function within the normal range and clinical outcomes are very relevant and needed. Apart 
from the reference limits of serum TSH, the optimal level of TSH to aim for during treatment 
(i.e. the target level) is not well known and this optimal TSH level could be different for each 
individual.
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These crucial questions are at the core of this PhD project and serve as the basis on which 
the studies described in this thesis have been designed. The general aim of this thesis is to 
investigate short- and long-term effects of subtle differences in thyroid function and iodine 
status in the general population in order to provide new information that can be taken into 
account when 1) assessing the reference range of serum TSH and 2) to identify factors that 
should be taken into account when assessing the optimal TSH level for a patient during thyroid 
hormone replacement therapy.
This introductory chapter provides background information on thyroid function and iodine 
intake as well as an overview of previous studies regarding thyroid function within the normal 
range and iodine status in the general population. The research questions, resulting from this 
information, are formulated and the studies conducted will be introduced.  
Thyroid function and thyroid function disorders
Background information on thyroid function 
The thyroid gland produces the hormones thyroxine (T
4
) and triiodothyronine (T
3
), which exert 
effects virtually on all organ systems. Serum thyroid hormone levels are maintained within 
narrow limits by a regulatory mechanism that is very sensitive to small changes in circulating 
free hormone concentrations (figure 1). TSH, produced by the thyrotroph cells in the anterior 
pituitary gland, stimulates the thyroid gland to secrete T
4
 and T
3
. TSH production is controlled 
by thyrotropin-releasing hormone (TRH), which is produced in the parvocellular region of the 
paraventricular nuclei of the hypothalamus. TRH is distributed throughout the hypothalamus, 
but its content is highest in the median eminence and paraventricular nuclei. TSH secretion is 
down-regulated by the negative feedback of thyroid hormones (T
4
 and T
3
) on the hypothalamus 
and the pituitary gland (figure 1). Thyroid hormones are essential for the development and 
function of all organ systems, in particular the brain. Adequate synthesis of thyroid hormones 
requires on one hand a sufficient iodine intake and on the other hand the capacity of the 
thyroid gland to metabolize iodine and to incorporate it in organic compounds. Thyroid diseases 
are common in the general population, however the incidence of thyroid function disorders 
varies among different populations.1-4 
Overt primary hypothyroidism is characterized by decreased serum free T
4
 (FT
4
) and 
increased serum TSH levels. An elevated serum TSH level associated with a normal FT
4 
serum concentration is defined as subclinical primary hypothyroidism. In the eastern part 
 1
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of the Netherlands, the prevalence of overt primary hypothyroidism and subclinical primary 
hypothyroidism is 0.4% and 4.0%, respectively.4 The most common cause of primary 
hypothyroidism in iodine-sufficient areas is chronic autoimmune (Hashimoto’s) thyroiditis. 
Iatrogenic causes such as thyroidectomy, radioiodine treatment, external radiation therapy and 
medications like amiodarone or lithium can also cause hypothyroidism. Central hypothyroidism 
is characterized by a low FT
4
 serum concentration and a serum TSH concentration which is not 
appropriately elevated. It is caused by either hypothalamic (tertiary hypothyroidism) or pituitary 
(secondary hypothyroidism) disorders. Hypothyroidism causes a generalized reduction of the 
metabolic rate that results in symptoms like fatigue, cold intolerance, weight gain, constipation 
and musculoskeletal symptoms. Moreover, severe hypothyroidism can cause hypothermia, 
anemia, hyponatremia, increase of serum creatinine, bradycardia, decreased cardiac output, 
edema, pericardial effusion, hypertension, hypercholesterolemia, oligo- or amenorrhea, 
neurological dysfunction and myxedema coma.5, 6 Overt hypothyroidism either primary or 
central requires replacement therapy with thyroid hormones.
CHAPTer 1 | General introduction
13
Figure 1.  
Thyrotropin-releasing hormone (TRH) increases the secretion of thyrotropin (TSH), which stimulates the synthesis and 
secretion of trioiodothyronine (T
3
) and thyroxine (T
4
) by the thyroid gland. T
3
 and T
4
 inhibit the secretion of TSH, both di-
rectly and indirectly by suppressing the release of TRH. T
4
 is converted to T
3
 in the liver and many other tissues by the ac-
tion of T
4
 monodeiodinases. Some T
4
 and T
3
 is conjugated with glucuronide and sulfate in the liver, excreted in the bile, 
and partially hydrolyzed in the intestine. Some T
4
 and T
3
 formed in the intestine may be reabsorbed. Reproduced with 
permission from: Ross DS. Thyroid hormone synthesis and physiology. In: UpToDate, Post TW (Ed), UpToDate, Waltham, 
MA. (Accessed on 1-4-2015). Copyright © 2015 UpToDate, Inc. For more information visit www.uptodate.com.
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Overt primary thyrotoxicosis is characterized by increased serum FT
4
 and decreased serum 
TSH levels. Subclinical primary thyrotoxicosis is characterized by a decreased serum TSH and a 
normal serum FT
4
 level. In the eastern part of the Netherlands, the prevalence of overt primary 
thyrotoxicosis and subclinical primary thyrotoxicosis is 0.4% and 0.8%, respectively.4 The 
most common causes of thyrotoxicosis are Graves’ disease, multinodular toxic goitre, toxic 
adenoma and thyrotoxic phase of subacute thyroiditis. Thyrotoxicosis caused by increased TSH 
production by a pituitary tumor is rare. The classic symptoms of thyrotoxicosis are weight loss, 
heat intolerance, tremor, palpitations, anxiety, increased frequency of bowel movements and 
shortness of breath. Thyrotoxicosis can also cause increased cardiac output, hypertension, atrial 
fibrillation, osteoporosis and neuropsychiatric diseases.5, 7 Different strategies can be applied 
for the treatment of overt thyrotoxicosis, including medication to inhibit thyroid hormone 
synthesis and/or release or methods that reduce the quantity of thyroid tissue (e.g. radioiodine 
or surgery).
Subclinical thyroid dysfunction can be associated with the same symptoms and diseases as 
overt thyroid dysfunction, although symptoms are generally less severe and the associations are 
generally less strong and more controversial as shown by the conflicting results of numerous 
studies.8, 9 The benefit of treatment of subclinical thyroid dysfunction is even more debated, as 
several double-blind placebo-controlled studies have shown a lack of improvement of symptoms 
and outcomes in subclinical primary hypothyroidism.8-10 At present, in the Netherlands, 
treatment of subclinical hypothyroidism is only recommended in the presence of symptoms of 
hypothyroidism.11 Treatment of subclinical thyrotoxicosis is recommended in the presence of 
symptoms of thyrotoxicosis, osteoporosis, atrial fibrillation or other cardiac co-morbidity.11 
Each individual has an own set-point of the hypothalamic-pituitary-thyroid axis.12 Variation of 
serum TSH, (free) T
4
 and T
3
 levels within individuals is much smaller than between individuals. 
The width of the 95% confidence interval of thyroid hormone levels in an individual is 
approximately half that of the population.12 Consequently, it is possible that a TSH level may be 
abnormal for an individual but still is within the laboratory reference limit. 
For some time, lowering the upper limit of the reference range of serum TSH has been 
debated.13-20 Reasons to question the present reference range of TSH are the high proportion 
of individuals whose serum TSH level is less than 2.5 mIU/L, the higher prevalence of thyroid 
autoantibodies in individuals with serum TSH level > 2.5 mIU/L and the observation that people 
with TSH levels between 2.5 and 4.5 mIU/L have an increased risk of progression to overt 
hypothyroidism.13, 21 However, since about 20% of the subjects without known thyroid disease, 
without thyroid autoantibodies and with normal thyroid ultrasound has a TSH level between 2.5 
CHAPTer 1 | General introduction
15
mIU/L and 4.5 mIU/L and no firm evidence is available that lowering the upper limit of normal 
will provide any short- or long-term benefit for subjects, the upper limit of the reference range 
of TSH remained unchanged.14, 16, 17 The question whether TSH level in the upper or lower 
part of the reference range is associated with clinical symptoms, cardiovascular risk factors, 
morbidity or mortality, is very important for the ongoing debate on narrowing the reference 
interval. In the past few years, several studies have investigated the relationship between thyroid 
function within the normal range and several outcomes. 
Previous studies regarding thyroid function within the normal range and clinical 
outcome parameters 
In the past few years, several studies have investigated the relationship between thyroid 
function within the reference range and several clinical outcomes including cardiovascular risk 
factors and morbidity, renal function and bone mineral density. Numerous previous studies 
examined the relationship between thyroid function within the normal range and cardiovascular 
risk factors, such as blood pressure, serum cholesterol, insulin sensitivity and adiposity. These 
studies reported conflicting results. Six studies found a positive association between TSH level 
within the normal range and systolic and/or diastolic blood pressure22-27 and one study found 
a positive association between FT
4
 level and systolic and diastolic blood pressure.28 However, 
10 studies found no association between thyroid function within the normal range and blood 
pressure at all.29-38 The majority of the studies examining the association between thyroid 
function within the normal range and serum lipid levels found that low-normal thyroid function 
was associated with less favorable lipid concentrations23, 28, 34, 35, 37-43, whereas 3 studies did 
not yield this association.29, 31, 32 Five studies showed an association between thyroid function 
within the normal range and insulin resistance28, 31, 35, 37, 44, but 3 other studies could not 
confirm this relationship.29, 32, 34 Recently, the studies investigating the relationship between 
TSH within the normal range and adiposity were reviewed.45 Of the 29 studies included in the 
review, 18 studies showed a positive relationship between measures of adiposity and serum 
TSH. In conclusion, of the cardiovascular risk factors, lipid concentration was most consistently 
associated with thyroid function within the normal range. The selected upper limit of TSH 
differed among all the studies, as well as the characteristics of the study population and the 
adjustment for potential confounders. These differences might explain the discrepancies of the 
study results.
Other studies investigated the relationship between thyroid function within the normal range 
and cardiovascular morbidity. Three large population-based studies found an association 
between high-normal thyroid function and atrial fibrillation.46-48 One study showed that higher 
levels of TSH within the normal range were associated with an increased risk of myocardial 
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infarction in patients with clinically manifest vascular disease.49 
Another large population-based study of 29,480 individuals (the HUNT study) investigated 
the relationship between the thyroid function within the normal range and renal function. In 
this study, TSH level within the reference range was negatively associated with the estimated 
glomerular filtration rate (eGFR) and the prevalence of chronic kidney disease (eGFR<60 ml/
min/1.763m2) was higher in individuals with low normal thyroid function.50 This study was a 
cross-sectional survey, therefore no conclusion concerning causality could be made. 
Several studies investigated the association between thyroid function within the normal range 
and bone mineral density (BMD) and these studies yielded conflicting results as well. Most of 
them showed an association between high-normal thyroid function and low BMD, osteopenia, 
osteoporosis or fracture risk.51-56 By contrast, two large population-based studies found no 
relationship between thyroid function within the normal range and BMD.57, 58 The discrepancy 
between these studies may be explained by the heterogeneity of the studies. There were 
differences in study population (clinical samples versus population-based studies), differences in 
reference limits of TSH, differences in measurement of BMD (lumbar spine versus hip or distal 
site of the forearm) and differences in adjustment for confounders. 
Only few studies investigated the relationship between thyroid function within the normal 
range and mortality and these studies also reported conflicting results. Some studies showed 
that a high-normal thyroid function is positive associated with mortality.59-62 Another study, 
comprising adults of 20 years or older, showed that higher TSH levels are associated with 
cardiovascular mortality in women.63 Other studies showed no association at all between 
thyroid function within the normal range and mortality.49, 64 The discrepancy of the results of 
previous studies investigating the association between thyroid function and mortality can be 
partially explained by the differences in study populations.
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Figure 2.
Simplifi ed overview of the relationship between serum TSH within the normal range and clinical parameters. 
research questions and conducted studies
As described above, several studies have investigated the relationship between thyroid function 
within the normal range and cardiovascular risk factors, morbidity and mortality. Data on the associ-
ation between thyroid function within the normal range and the presence of symptoms are scarce. 
The fi rst aim of this thesis was to investigate the association between thyroid function within the 
normal range and symptoms. Fatigue and depressive symptoms are frequently reported by patients 
with thyroid dysfunction and these are very relevant symptoms impairing quality of life of patients.65, 
66 We hypothesized that there is a relationship between thyroid function within the normal range 
and fatigue and depressive symptoms. The Nijmegen Biomedical Study (NBS) provided us the op-
portunity to test these hypotheses (Chapter 2 and 3). The NBS is a large population-based survey 
undertaken in the eastern part of the Netherlands. A total of 22,451 age- and sex-stratifi ed random-
ly selected adults received a questionnaire on lifestyle, medical history and symptoms (including the 
presence and severity of fatigue and depressive symptoms). Of each age-group (range 5 years), 750 
men and 750 women were invited to participate. A total of 9,350 subjects, receiving a question-
naire, responded (response rate: 42%). Of the responders, 6,434 subjects (69%) gave permission for 
blood withdrawal and several items including thyroid hormones were measured in serum. 
A second aim of this thesis was to investigate the relationship between thyroid function within 
the normal range and mortality, a long term outcome. Some previous studies suggest that age 
might infl uence the association between thyroid function and mortality.67, 68 However, the total 
number of young participants and oldest elderly is limited in most studies. The NBS comprises 
randomly selected adults of all age groups. Therefore, this population-based study provided us 
the opportunity to investigate the infl uence of age on the relationship between thyroid function 
and mortality (Chapter 4).
Low-normal range
Higher incidence/prevalence of
• Atrial ﬁ brillation
•  Osteoporosis with increased fracture risk
High-normal range
Serum TSH within the normal range
• Less favorable lipid concentrations
• Adiposity
• Higher blood pressure
• Insulin resistance
Higher prevalence of
• Chronic kidney disease
• Myocardial infarction (female)
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A factor that one should take into account when interpreting studies concerning the 
association between thyroid function and symptoms, diseases or mortality, is the variation 
of thyroid function. The overall variation of the thyroid function measurements consists of 
biological variation, preanalytical variation and analytical variation.12, 69-71 The variation in thyroid 
function measurements blurs the association between thyroid function and the outcomes of 
interest (figure 3,72). This is called the regression dilution bias.72-75 Studies, based on one single 
measurement of thyroid function, underestimate the association between thyroid function and 
symptoms, diseases and mortality. This is especially the case in studies with a long follow up 
period. The magnitude of underestimation of associations between several cardiovascular risk 
factors and cardiovascular diseases and mortality has been previously described.73, 74, 76, 77 For 
the relationship between thyroid function and symptoms, diseases or mortality, the magnitude 
of this underestimation is still unknown. Therefore, a third aim of this thesis was to estimate 
the magnitude of underestimation of the relationship between thyroid function and symptoms, 
diseases and mortality due to variation of thyroid function. In order to determine the magnitude 
of this underestimation due to regression dilution bias, we used repeated measurements of 
thyroid function (with an interval of 2-4 years) in two large population-based surveys, the NBS 
and the Rotterdam Study (Chapter 5).
Figure 3. The effect of variation of the exposure variable on the outcome variable. With no variation in measurement of 
the exposure variable (panel a), the slope of the line describes the error-free association between exposure variable and 
outcome variable. Variation of the exposure variable results in an attenuation of the slope (panel b) and the association 
between the exposure variable and outcome variable is underestimated.72
exposure Variableexposure Variable
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Iodine and thyroid function
Background information on iodine 
Iodine is an essential micronutrient and an important component of thyroid hormones. The 
thyroid hormones T
4
 and T
3 
contain 4 and 3 iodine atoms, respectively. Iodine must be provided 
in the diet. Iodine deficiency can cause thyroid dysfunction, goiter and cretinism.78 Iodine excess 
can also cause thyroid dysfunction. Monitoring the iodine status and maintaining an optimal 
iodine intake in the population is very important to prevent brain damage in newborns and 
thyroid function disorders at all ages. Iodine is a trace element in the crust of the earth and its 
distribution is quite variable. Many areas, particularly inland and mountainous regions, have 
minimal iodine concentrations in the crust of the earth, while others, often coastal regions, 
have sufficient or even excessive iodine concentrations. Soil and ground water (used for water 
supply systems) vary greatly in iodine content between different areas. Sea products and fish 
also contain iodine. Iodine deficiency remains a global public health problem.79
In the past, mild iodine deficiency was present in the eastern and southern part of the 
Netherlands.80-82 Iodine supplements were instituted as of 1935. Since then, several additional 
measures, like the compulsory use of iodized salt in bakeries, instituted in 1963, were taken 
to achieve a daily intake of iodine within the optimal range as recommended by the WHO.83 
Currently, the iodine status of the Netherlands is considered to be adequate, based on 
studies regarding the iodine intake and urinary excretion of iodine in several regions in the 
Netherlands.79, 84-88 
Previous studies regarding the relationship between iodine status and thyroid function 
Previous population studies have shown that in populations with a history of mild or moderate 
iodine deficiency, the average TSH levels tend to decrease with age whereas FT
4
 levels tend to 
increase with age, which is probably due to the gradual development of autonomous function 
of the thyroid gland.4, 89, 90 In case of mild iodine deficiency, low iodine intake might lead to a 
reduced T
4
 and T
3
 production. In order to prevent this, several TSH-independent autoregulatory 
mechanisms within the thyroid are triggered, such as an increase in vascularity, an increase in 
iodine uptake and deiodination of T
4
 to T
3
.91 If these mechanisms fail, TSH levels will rise in 
response to a lower thyroid hormone production. TSH stimulates follicular cell replication and 
due to the higher replication rate, the chance of activating mutations in the TSH-receptor gene 
leading to TSH-independent growth and function, is increased.92 This and other mechanisms 
lead to autonomous function of the thyroid and, especially when iodine intake is supplemented, 
to hyperthyroidism. In subjects of the NBS, performed in Nijmegen, a municipality in the 
eastern part of the Netherlands with a history of mild iodine insufficiency, TSH level is negatively 
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associated with age and FT
4
 is positively associated with age.4 In contrast with the decrease of 
TSH level with age in populations with an iodine deficiency, TSH levels tends to increase with 
age in populations with high iodine intake.3, 93-96 
research questions and conducted studies 
The previous population studies, showing a negative association between TSH levels and age in 
iodine insufficient areas, are cross-sectional studies. These findings raise the question whether 
such an age-thyroid function relation is apparent also in longitudinal analyses and, if so, 
whether it reflects an actual iodine deficiency. To answer this question, we analyzed longitudinal 
data on thyroid function and data on iodine status of participants of the NBS (Chapter 6).
Previous studies showed that current differences in iodine intake influence the relationship 
between thyroid function and age. Because iodine insufficiency in the past might cause an 
ongoing increase of FT
4
 and decrease of TSH levels even after attaining an adequate iodine 
status, we hypothesized that there also might be differences in the present relationship 
between thyroid function and age in case of differences in iodine intake in the past. Moreover, 
the relationship between thyroid function and age could be used as an indicator of present or 
historical iodine status. So, a further aim of this thesis was to investigate the effect of historical 
iodine status of a population on the current relationship between thyroid function and age. In 
order to test this hypothesis, we examined the relationship between thyroid function and age in 
several regions in the Netherlands which are iodine sufficient at present but with a difference in 
iodine intake in the past (Chapter 7). 
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CHAPTer 2
Is there a relationship between fatigue perception 
and the serum levels of thyrotropin and free 
thyroxine in euthyroid subjects?
Annenienke C. van de Ven, Romana T. Netea-Maier, Femmie de Vegt, H. Alec Ross, 
Fred C.G.J. Sweep, Lambertus A. Kiemeney, Ad R.M.M. Hermus, Martin den Heijer. 
Thyroid 2012 22 1236-1243.
30
Abstract
Background  
Thyrotoxicosis and hypothyroidism are associated with fatigue. Here we studied euthyroid 
subjects to determine if there was a relationship between serum thyroid stimulating hormone 
(TSH), free thyroxine (FT
4
) and thyroperoxidase antibodies and fatigue.
Methods  
A total of 5,897 participants of the Nijmegen Biomedical Study received a questionnaire and 
serum TSH (normal range 0.4-4.0 mIU/L) and FT
4
 (normal range 8-22 pmol/L) were measured. 
Fatigue was evaluated by the RAND-36 and the Shortened Fatigue Questionnaire (SFQ). 
results  
Euthyroid subjects with a serum TSH level of 0.4-1.0 mIU/L had a lower RAND-36 vitality score 
(65.2 versus 66.8, regression coefficient (RC) -1.6, 95% CI -2.6 ; -0.5, p-value 0.005) and a 
higher SFQ score (11.7 versus 11.0, RC 0.6, 95% CI 0.2 ; 1.0, p-value 0.004) than those with 
a TSH of 1.0-2.0 mIU/L. Those with a serum FT
4
 of 18.5-22 pmol/L reported fatigue more often 
(52.5% versus 33.3%, relative risk (RR) 1.4, 95% CI 1.0 ; 1.9, p-value 0.03), had a lower RAND-
36 vitality score (61.7 versus 66.6, RC -4.4, 95% CI -8.1 ; -0.6, p value 0.02) and a higher SFQ 
score (13.2 versus 11.0, RC 1.9, 95% CI 0.4 ; 3.3, p-value 0.01) than subjects with a FT
4
 level of 
11.5-15 pmol/L. In comparison to euthyroid subjects without known thyroid disease, euthyroid 
subjects with previously known thyroid disease reported fatigue more often (52.3% versus 
34.0%, RR 1.3, 95% CI 1.0 ; 1.5, p-value 0.025), had a lower RAND-36 vitality score (61.4 
versus 66.3, RC -2.9, 95% CI -5.3 ; -0.6, p-value 0.015) and a higher SFQ score (13.7 versus 
11.1, RC 1.4, 95% CI 0.5 ; 2.3, p-value 0.002).
Conclusion  
In euthyroid individuals without a history of thyroid disease there is a modest relationship 
between thyroid function and fatigue with subjects having apparently higher production of T
4
 
experiencing more fatigue. Subjects with a history of thyroid disease, but with normal TSH and 
FT
4
 concentrations, experience more fatigue than the general population. The reasons for this 
are unclear but subtle abnormalities in the dynamics of thyroid hormone secretion should be 
considered. 
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Introduction
Thyroid dysfunction is common in the general population.1-4 Fatigue is a frequently reported 
symptom of patients with both hyper- and hypothyroidism.5-9 Fatigue is also one of the most 
relevant symptoms for patients with thyroid dysfunction impairing their quality of life.9, 10 As for 
mild degrees of thyroid dysfunction, Canaris et al. reported more symptoms, including feeling 
more tired, in subclinically hypothyroid subjects in comparison to euthyroid subjects in a large 
population-based study.2 In contrast, Grabe et al. found no increase of fatigue in subjects with 
subclinical and overt hypo- or hyperthyroidism in a population-based study.11 
In the absence of suitable methods for measuring thyroid hormone and thyroid stimulating 
hormone (TSH) production rates in groups of patients, by generally accepted definition, subjects 
with serum TSH and free thyroxine (FT
4
) concentrations within the normal range are considered 
to be euthyroid. Previous studies have shown an association between variations in serum TSH 
and FT
4
 concentrations within the normal range and cardiovascular risk, blood pressure, body 
mass index, incidence of atrial fibrillation and serum cholesterol.12-17 These results raise the 
question of whether there is also an association between fatigue and serum TSH and FT
4
 within 
the normal range. Recently, an association between the level of thyroperoxidase antibodies 
(TPOAbs) and fatigue has been described in euthyroid women with a goiter.18 This raises the 
question whether TPOAb levels are associated with fatigue in the general population.   
The present study had several goals. The first was to investigate whether unsuspected thyroid 
dysfunction (i.e. overt or subclinical thyrotoxicosis or overt or subclinical hypothyroidism) as 
uncovered in a population, was associated with the prevalence and severity of fatigue. The 
second was to investigate whether, in subjects whose serum TSH and FT
4
 are in the normal 
range, there is a relationship between the levels of serum TSH or serum FT
4 
and the prevalence 
and severity of fatigue. The last was to determine in apparently euthyroid subjects (i.e. normal 
TSH and FT
4
) whether there is an association between the presence of TPOAbs and fatigue. 
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Methods
Study participants 
The subjects of this study were participants of the Nijmegen Biomedical Study (NBS), a large, 
population-based survey performed in Nijmegen, a town in the eastern part of The Netherlands. 
Details of this study have been described previously.4 Approval to conduct the study was 
obtained from the Institutional Review Board. A total of 22,451 age- and sex-stratified randomly 
selected adults received a questionnaire on lifestyle, medical history and symptoms. Of each 
age-group (range 5 years), 750 men and 750 women were invited to participate. We excluded 
pregnant women and subjects using medication interfering with thyroid function such as 
lithium, amiodarone, kelp, oral glucocorticosteroids and/or dopamine agonists because of the 
possible effect of these conditions and medications on thyroid function. In order to investigate 
the population without known thyroid disease, we excluded the subjects with previously known 
thyroid disease, subjects with the use of thyromimetic and/or thyrostatic drugs, and subjects 
with a history of thyroid surgery and/or radioactive iodine treatment.
Laboratory methods 
Serum TSH was measured by an immunoluminometric assay on a random-access analyzer 
(Architect; Abbott Diagnostics Division). The reference interval used in our laboratory is 0.4-4.0 
mIU/L. Serum FT
4
 was measured with a luminescence enzyme immunoassay on a random-
access assay system (Vitros ECI; Ortho Clinical Diagnostics). Our laboratory reference interval 
is 8.0-22.0 pmol/L. Antibodies against TPO (TPOAbs) were measured with a fluorescence 
immunoenzymometric assay for the quantitative measurement of the IgG class of anti-
thyroperoxidase antibodies (AxSYM Anti-TPO; Abbott Diagnostics Division). The reference 
interval was defined as <12 kIU/L (data provided by manufacturer). More details about these 
measurements are described elsewhere.4 Thyroid function was classified as overt thyrotoxicosis 
if TSH was <0.4 mIU/L and FT
4 
was >22 pmol/L and it was classified as subclinical thyrotoxicosis 
if TSH was <0.4 mIU/L and FT
4
 was ≥8 pmol/L and ≤ 22 pmol/L. Thyroid function was classified 
as overt hypothyroidism if TSH was >4.0 mIU/L and FT
4
 was <8 pmol/L and as subclinical 
hypothyroidism if TSH was >4.0 mIU/L and FT
4
 was ≥8 pmol/L and ≤ 22 pmol/L. When both 
TSH and FT
4
 were within normal range, thyroid function was classified as euthyroidism. When 
either TSH or FT
4
 was not within the normal range, thyroid function was classified as thyroid 
dysfunction. Subjects with overt thyrotoxicosis, subclinical thyrotoxicosis, overt hypothyroidism, 
or subclinical hypothyroidism were considered to have thyroid dysfunction. 
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Questionnaire 
The questionnaire contained questions about gender, age, weight, height, lifestyle, medical 
history and the use of medication. The presence of the symptom fatigue was evaluated by the 
question: ‘Do you feel tired?’. Data on the presence of the symptom fatigue were missing in 
119 subjects. The subscale vitality (energy and fatigue) of the RAND-36 Item Health Survey 1.0 
was used to determine the intensity of fatigue1.9 The items of the subscale vitality are identical 
to the MOS SF-36.20 The subscale vitality of the RAND-36, translated in Dutch, has a good 
internal reliability (Cronbachs α: 0.82).21, 22 It consists of four questions: ‘How much of the time 
during the past 4 weeks...- did you feel full of life? - did you have a lot of energy? - did you 
feel worn out? - did you feel tired?’. The participants choose the best option of the 6 possible 
answers given for each question: ‘all of the time’, ‘most of the time’, ‘a good bit of the time’, 
‘some of the time’, ‘a little of the time’, or ‘none of the time’. All items were scored on a 0 
to 100 range and recoded so, that a high score defined a more favourable health state. The 
average score of the 4 questions was calculated. When 1 or 2 items were missing, the average 
score of the other 2 or 3 questions was used. If 3 or 4 items were missing, the total score was 
defined as missing and not used for the analyses. The score of the subscale vitality of the RAND-
36 was missing in 178 subjects. A higher score is associated with having more energy and 
being less fatigue, with a maximum score of 100. The average score of the subscale vitality of 
the RAND-36 in a Dutch cohort, consisting of 1063 subjects, aged 18-89 years, was 67.4 (SD 
19.9).22 In this cohort, young adults (19-24 years old) scored on average 69.2 points, whereas 
elderly (75-85 years old) scored on average 60.1 points. 
In addition, the Shortened Fatigue Questionnaire (SFQ) was also used to determine the intensity 
of the fatigue.23, 24 The SFQ is a short and easy to use instrument to determine the intensity of 
fatigue. The SFQ has a good internal reliability (Cronbach-α: 0.88) and discriminating validity. 
It consists of four statements: “I feel tired”, “I tire easily”, “I feel fit”, and “I feel physically 
exhausted”. The participants rated the statements for the degree of being true at a 7-point 
scale and for each answer points were granted. A higher score is associated with being more 
tired, with a maximum score of 28 points. Healthy adults, without any stressful conditions, 
score on average 5-8 points, whereas for example patients with cancer score on average 13-21 
points.23 The SFQ score was missing in 497 subjects. 
Statistical analysis  
The body mass index (BMI) was calculated by dividing the body weight (kg) by the square of 
the height (m). Relative risks along with the 95% confidence intervals (CI) were estimated using 
loglinear regression analyses, with fatigue as the dependent variable and thyroid function class 
and TSH and FT
4
 subclasses within the normal range as the independent variables.25-27 Also the 
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presence of TPOAbs (defined as >12kIU/mL according to the reference interval provided by the 
manufacturer) and the presence of known thyroid disease were used as independent variables 
in the loglinear analysis. 
In order to compare the score of the vitality subscale of the RAND-36 and the SFQ score of 
each thyroid function class, we used linear regression analyses with the fatigue score as the 
dependent variable and thyroid function class as the independent variable. Within the normal 
range of thyroid function, we used subclasses of TSH and FT
4
 for linear regression analyses with 
the score of the subscale vitality of the RAND-36 or the SFQ score as the dependent variable 
and the TSH subclasses and FT
4
 subclasses as the independent variables. The presence of TPOAb 
levels was also used as the independent variables for linear regression analyses with the score of 
the subscale vitality of the RAND-36 or the SFQ score as the dependent variable. 
All regression analyses were adjusted for gender, age, BMI and smoking status in order to 
eliminate possible confounders. In addition, we adjusted for a medical history of chronic 
obstructive pulmonary disease (COPD)/asthma, rheumatoid disease, cardiovascular disease 
(CVD), cancer, diabetes mellitus, kidney disease, liver disease and C-reactive protein (CRP) to 
rule out the possible confounding effect of non-thyroidal illness. We analysed the data with 
STATA version 11.0 (StataCorp, Texas).
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results
A total of 9350 subjects, receiving a questionnaire, responded (response rate: 42%). Of the 
responders, 6434 subjects (69%) gave permission for blood withdrawal. Of the responders, 
the subjects who gave permission for blood withdrawal differed only slightly from the subjects 
who did not donate blood samples: the mean age was 56 versus 53 years respectively, the 
percentage of women was 54% versus 50%, the prevalence of fatigue was 36% versus 37%, 
the mean RAND-36 vitality score was 65.7 versus 63.9 and the SFQ score was 11.4 versus 12.2. 
We excluded 47 pregnant women and 162 subjects using medication interfering with thyroid 
function. In addition, we excluded 328 subjects because of previously known thyroid disease.
Table 1.  
Characteristics of the population. 
Characteristic Total 
n=5897
Female 
n=3101
Male 
n=2796
Age (years) 55.6 ± 17.9 53.1 ± 18.1 58.5 ± 17.2
BMI (kg/m2) 25.2 ± 4.1 24.8 ± 4.5 25.6 ± 3.6
Smoking (n %) 1327 (22.5%) 652 (21.0%) 675 (24.1%)
Medical history of:
COPD/asthma (n %) 725 (12.3%) 375 (12.1%) 350 (12.5%)
CVD (n %) 586 (9.9%) 161 (5.2%) 425 (15.2%)
rheumatic disease (n %) 502 (8.5%) 329 (10.6%) 173 (6.2%)
cancer (n %) 453 (7.7%) 229 (7.4%) 224 (8.0%)
diabetes mellitus (n %) 321 (5.4%) 145 (4.7%) 176 (6.3%)
kidney disease (n %) 173 (2.9%) 87 (2.8%) 86 (3.1%)
liver disease (n %) 138 (2.3%) 79 (2.5%) 59 (2.1%)
CRP > 10 mg/L (n %) 544 (9.2%) 290 (9.4%) 254 (9.1%)
Fatigue (n %) 1989 (34.4%) 1195 (39.5%) 794 (28.9%)
RAND-36 score 66.2 ± 17.4 64.1 ± 17.3 68.6 ± 17.3
SFQ score 11.2 ± 6.4 12.0 ± 6.6 10.3 ± 6.1
TSH (mIU/L) 1.4 (0.9-2.0) 1.4 (0.9-2.0) 1.4 (0.9-1.9)
FT
4 
(
 
pmol/L) 13.3 (12-14.6) 13.3 (12-14.6) 13.3 (12-14.7)
TPOAbs positive (n %) 747 (12.7%) 520 (16.8%) 227 (8.1%)
Euthyroid (n %) 5439 (92.2%) 2823 (91.0%) 2616 (93.6%)
Data are reported as number (percent), mean ± standard deviation, or median (IQR).
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; CRP, C-reactive protein; 
SFQ, shortened fatigue questionnaire; TSH, thyrotropin; FT
4
, free thyroxine; TPOAbs, thyroperoxidase antibodies.
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The characteristics of the remaining 5897 subjects are shown in Table 1. The age ranged from 
18 years until 98 years. Female gender, a higher age, a higher BMI and a medical history of 
cardiovascular disease, cancer, diabetes, rheumatoid arthritis, asthma/COPD, renal disease, liver 
disease and a high CRP were all associated with a higher prevalence of fatigue.
Table 2 shows the prevalence of self-reported fatigue, the RAND-36 vitality subscale score and 
SFQ score according to the thyroid function class. Subjects with thyroid dysfunction reported 
fatigue more frequently (39.6%) than euthyroid subjects (34.0%), but this difference was 
not statistically significant. The relative risk was 1.2 (95% confidence interval (CI) 0.996 ; 1.4, 
p-value 0.055). After adjustment for possible confounders, the relative risk was 1.1 (95% CI 
0.9 ; 1.3, p-value 0.34). There was no statistically significant difference in RAND-36 score or 
SFQ score between euthyroid subjects and subjects with thyroid dysfunction, neither before nor 
after adjustment for possible confounders.
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The prevalence of fatigue, the score of the subscale vitality of the RAND-36 and the SFQ score 
by TSH and FT
4
 subclasses within the normal range (i.e. in euthyroid subjects) are shown in 
table 3. Within the normal range of TSH, subjects with a TSH level of 0.4-1.0 mIU/L had a lower 
RAND-36 vitality score (65.2 versus 66.8, mean difference -1.6, 95% CI -2.6 ; -0.5, p-value 
0.005) and a higher SFQ score (11.7 versus 11.0, mean difference 0.6, 95% CI 0.2 ; 1.0, 
p-value 0.004) than those with a serum TSH of 1.0 to 2.0 mIU/L, after adjustment for possible 
confounders. Subjects with a serum FT
4
 level of 18.5 to 22 pmol/L reported fatigue more often 
(52.5% versus 33.3%, relative risk 1.4, 95% CI 1.0 ; 1.9, p-value 0.03), had a lower RAND-36 
vitality score (61.7 versus 66.6, mean difference -4.4, 95% CI -8.1 ; -0.6, p value 0.02) and a 
higher SFQ score (13.2 versus 11.0, mean difference 1.9, 95% CI 0.4 ; 3.3, p-value 0.01) than 
subjects with a serum FT
4
 level of 11.5 to 15 pmol/L. Of the 1493 subjects with a TSH level 
between 0.4 and 1.0 mIU/L, 2.7% of the subjects (40 subjects) had a FT
4
 level between 18.5 
and 22 pmol/L. These 40 subjects reported fatigue more often (58% versus 36%, RR 1.6, 95% 
CI 1.2 ; 2.2, p-value 0.001), had a (not statistically significant) lower RAND-36 vitality subscale 
score (62.2 versus 65.2, RC -3.2, 95% CI -9.0 ; 2.5, p-value 0.27) and a higher SFQ score (13.6 
versus 11.6, RC 2.2, 95% CI 0.1 ; 4.3, p-value 0.04) than subjects with a TSH level between 0.4 
and 1.0 mIU/L and a FT
4
 level between 8 and 18.5 pmol/L. Of the 91 subjects with a FT
4 
level 
between 18.5 and 22 pmol/L, 44.0% of the subjects (40 subjects) had a TSH level between 0.4 
and 1.0 mIU/L. These 40 subjects did not differ from the 51 subjects with a TSH level between 
1.0 and 4.0 mIU/L in self-reported fatigue, RAND-36 vitality subscale score and SFQ score (self-
reported fatigue 58% versus 48%, RR 1.4, 95% CI 0.9 ; 2.1, p-value 0.11; RAND-36 vitality 
subscale score 62.2 versus 61.3, RC -0.2, 95% CI -7.6 ; 7.3, p-value 0.97; SFQ score 13.6 
versus 12.8, RC 1.5, 95% CI -1.3 ; 4.3, p-value 0.30). There were no differences in gender, BMI, 
smoking status or co-morbidity between the subclasses of TSH and FT
4
. However, subjects with 
a TSH level of 0.4-1.0 mIU/L and subjects with a serum FT
4
 level of 18.5 to 22 pmol/L were older 
(mean age 57.9 and 67.2 years respectively) than the reference group (mean age 54.6 and 54.1 
years respectively). Subanalyses using different age groups gave similar results regarding the 
association between the subclasses of TSH and FT
4
 levels within the normal range and fatigue 
(self-reported fatigue, RAND-36 vitality subscale score and SFQ score) (data not shown). 
There was no association between the prevalence of self-reported fatigue, the RAND-36 vitality 
subscale score or the SFQ score and the presence of TPOAbs, neither in euthyroid subjects nor 
in subjects with thyroid dysfunction (table 4). Subdividing the subjects with TPOAbs according 
to the level of TPOAbs did not change these results (data not shown).
When comparing the study population with the subjects, excluded because of previously known 
thyroid disorder, subjects with a known thyroid disorder reported fatigue more often (50% 
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versus 34.4%, RR 1.2, 95% 1.0 ; 1.4, p-value 0.03), had a lower RAND-36 vitality score (61.8 
versus 66.2, mean difference -2.6, 95% CI -4.5 ; -0.6, p-value 0.01) and a higher SFQ score 
(13.5 versus 11.2, mean difference 1.3, 95% CI 0.6 ; 2.1, p-value<0.001) than subjects without 
known thyroid disorder (table 5). Even in subjects who had serum TSH and FT
4
 concentrations 
in the normal range, those with previously known thyroid disease reported fatigue more often 
(52.3% versus 34.0%, relative risk 1.3, 95% CI 1.0 ; 1.5, p-value 0.025), and had a lower 
RAND-36 vitality score (61.4 versus 66.3, mean difference -2.9, 95% CI -5.3 ; -0.6, p-value 
0.015) and a higher SFQ score (13.7 versus 11.1, mean difference 1.4, 95% CI 0.5 ; 2.3, 
p-value 0.002). The median TSH of euthyroid subjects without previously known thyroid disease 
was 1.4 mIU/L (interquartile range (IQR) 1.0-1.9). The median TSH of subjects with known 
thyroid disease and TSH levels within normal range did not differ: 1.4 mIU/L (IQR 0.9-2.1). The 
median FT
4
 of euthyroid subjects without previously known thyroid disease was 13.3 pmol/L 
(IQR 12.1-14.6). The median FT
4
 of subjects with previously known thyroid disease and serum 
TSH and FT
4
 within the normal range was 14.3 pmol/L (IQR 12.5-15.9). This differed significantly 
from the FT
4
 levels of euthyroid subjects without previously known thyroid disease (RC 0.80, 
95% CI 0.5 ; 1.1, p-value<0.05 after adjustment for possible confounders ).  
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Discussion
In this cross-sectional population study, we found an association between the presence and 
severity of fatigue and low-normal serum TSH levels and high-normal FT
4
 levels. Although the 
magnitude of the differences was small and of dubious clinical significance, these results raise 
the question whether a serum TSH-value in the middle- or high-normal range would represent 
an optimal thyroid function. Indeed, the Rotterdam study has shown that a high-normal 
serum TSH level is associated with a lower risk of atrial fibrillation.16 However, other previous 
studies have shown a higher risk of cardiovascular mortality, an association with a higher blood 
pressure, a higher body mass index and a higher non-HDL cholesterol in subjects with serum 
TSH-values within the high-normal range.12-15, 17 These findings suggest that there may be 
different optimal serum TSH levels for each medical condition and symptom. 
Previous studies have reported conflicting results regarding the association of thyroid function 
and fatigue in the general population. Canaris et al. reported more symptoms, including 
an increase of tiredness in subclinically and overtly hypothyroid subjects in comparison to 
euthyroid subjects in the Colorado study.2 The Colorado thyroid disease prevalence study was 
a large, cross-sectional population study that examined the prevalence of abnormal thyroid 
function by measuring the serum TSH and FT
4
 in 25,862 participants in a statewide health fair 
in Colorado in 1995. Besides the prevalence of thyroid dysfunction, the relationship between 
abnormal thyroid function and symptoms was examined, among which the symptom of 
feeling more tired. Due to the larger study population, this study comprised more subclinically 
and overtly hypothyroid subjects in comparison to our study. Also, the symptom feeling more 
tired was evaluated as an increase of tiredness over time instead of tiredness as a current 
symptom. This may explain the discrepancy with our results with respect to the prevalence 
of fatigue in patients with overt or subclinical hypothyroidism. Another explanation is that 
the participants of our study were not aware of the fact that thyroid function was tested and 
therefore this could not have affected their response to the questionnaire. Grabe et al. found 
no increase in mental or physical complaints, including fatigue, in subjects with subclinical or 
overt hypo- or hyperthyroidism in a population study with 3790 participants of the Study of 
Health in Pomerania (SHIP). Interestingly, subjects with overt or subclinical hyperthyroidism 
seemed to have less complaints in comparison to euthyroid subjects, but the prevalence of 
the symptom fatigue did not differ significantly.11 These results are in accordance with the 
results in our study. Neither of the previous studies examined the association between TSH 
and FT
4
 within the normal range and fatigue or used a validated test to establish the severity 
of fatigue.
 2
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In contrast with the association we found between the presence and severity of fatigue and 
low-normal TSH and high-normal FT
4
 levels, we could not detect an obvious association 
between overt or subclinical hypo- or hyperthyroidism and fatigue. This is also in contrast with 
the high prevalence of fatigue in patients with known thyroid dysfunction.5-7 One explanation 
may be that if thyroid dysfunction has led to complaints like tiredness, it is likely that these 
subjects have sought medical care and received therapy. These subjects were excluded from 
our analyses. This may has led to an underestimation of the association between thyroid 
dysfunction and fatigue in our study. Another explanation may be that thyroid dysfunction 
of the subjects in this study is less severe than that of the population consisting of referred 
patients. A third explanation might be that in our study, only a single blood sample was 
obtained for determining the thyroid hormone levels. Thyroid dysfunction can be transient and 
normalize spontaneously. These subjects might be less likely to complain of fatigue.  
However, based on our data we believe that this is not the only explanation for this discrepancy. 
The prevalence of fatigue in subjects with thyroid dysfunction in our study was 39.6%, 
only slightly higher than the prevalence of fatigue in euthyroid patients, which was 34.0%. 
Because of the high prevalence of both fatigue and thyroid (subclinical) dysfunction in the 
general population, it is likely that many patients who seek medical care because of fatigue, 
happen to be tired and by coincidence also have thyroid dysfunction, without any causal 
relationship. Patients with fatigue are more likely to have their thyroid status tested by the 
general practitioner and thyroid dysfunction will be found more often, despite the absence 
of a causal relationship. This kind of selection bias is called confounding by indication.28 
Theoretically, treatment of thyroid dysfunction in these cases would not resolve the symptom 
fatigue. Although it is difficult to extend these findings of an epidemiological study to individual 
patients, we hypothesize that this might be the reason why in clinical practice, a subset of 
patients with thyroid dysfunction still complains of fatigue, despite optimal treatment and 
despite achieving euthyroidism. Our finding that subjects with known thyroid disease reported 
fatigue more often, had a lower RAND-36 vitality score and had a higher SFQ score, despite 
normal serum TSH and FT
4
 levels, supports this hypothesis. This hypothesis is also compatible 
with previous randomized controlled studies in which treatment of subclinical hypothyroidism 
and subclinical thyrotoxicosis had no effect on health related quality of life and symptoms.29, 30  
Confounding by indication is one explanation for the finding that subjects with known thyroid 
disease reported fatigue more often, regardless of normal serum TSH and FT
4
 levels. Another 
explanation might be that the underlying disease, like chronic autoimmune thyroiditis, Graves’ 
disease or goiter, may cause fatigue regardless of the presence of thyroid dysfunction or is 
associated with other diseases which may cause fatigue as well. Also, the fact that subjects 
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are aware of having thyroid disease may influence their feeling of well-being and have an 
impact on their quality of life, which may result in a higher fatigue score. In addition, subtle 
abnormalities in the dynamics of thyroid hormone secretion, even within the normal range, 
should be considered; the FT
4
 levels of subjects with known thyroid disease and with thyroid 
hormone levels within the normal range were slightly higher in comparison to euthyroid 
subjects without known thyroid disease. Similar to our results, Engum et al. have reported an 
association between previously known thyroid disease and depression and anxiety, independent 
of thyroid function, in a large population based survey.31  
We found no association between the level of TPOAbs and fatigue. This is in contrast with 
the recently described association between TPOAbs and both the presence of fatigue and the 
vitality subscale score of the SF-36 questionnaire.18 Perhaps the difference in study population is 
the cause of this discrepancy. The study of Ott et al. comprised euthyroid women with a benign 
goiter. Our study was population-based, comprising both men and women, without known 
thyroid disease.  
Our study has some limitations. Because of the cross-sectional observational nature of our 
study, no causal relationship or lack of causal relationship can be determined. Second, 
the results in the group of patients with overt hypothyroidism or thyrotoxicosis should be 
interpreted cautiously, as only a small number of participants were found to have an overt 
thyroid dysfunction. We did not measure T
3
, so we might have missed some cases of overt 
thyrotoxicosis in subjects with normal FT
4
 and elevated T
3
 and misclassified those subjects as 
having a subclinical thyrotoxicosis. Third, antibodies against thyroglobulin were not measured in 
this epidemiological survey, so we might have missed some cases of autoimmune thyroiditis.32 
Fourth, despite the fact that the subscale vitality of the RAND-36 and the SFQ we used have 
been validated as excellent tools to screen for the presence and severity of fatigue, these 
instruments have only a limited value with respect to their ability to differentiate and quantify 
all the dimensions of fatigue. It is difficult to establish the clinical meaningfulness of a 1 point 
higher score on a fatigue scale. Finally, we cannot rule out a selection bias due to a difference 
in fatigue or thyroid function in the responders group versus the non-responders group and we 
cannot rule out the presence of other, unmeasured possible confounders.
In conclusion, within the normal range of TSH and FT
4
, fatigue seemed more severe in subjects 
with low-normal TSH levels and high-normal FT
4 
levels than middle-normal TSH and FT
4
 levels, 
although the effect was small. Subjects with a history of thyroid disease, but with normal TSH and 
FT
4
 concentrations, experience more fatigue than the general population. The reasons for this are 
unclear but subtle abnormalities in the dynamics of thyroid hormone secretion should be considered. 
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Addendum
In order to assess the percentage of cases with fatigue in subjects with thyroid dysfunction that 
is due to the thyroid dysfunction, we calculated the attributable risk and population attributable 
risk. These calculations did not get through the review process of the manuscript. However, 
in the context of this thesis, the attributable risk provides clarity on the relationship between  
thyroid dysfunction and symptoms. 
We calculated the attributable risk with use of the formula (R
1
-R
o
)/R
1
, where R
1
 is the risk of the 
exposed (prevalence of fatigue in subjects with thyroid dysfunction) and R
0
 is the risk of the 
non-exposed (prevalence of fatigue in euthyroid subjects). The population attributable risk was 
calculated with the formula (R-R
0
)/R, where R is the risk of fatigue in the total population and 
R
0
 is the risk of the non-exposed (euthyroid subjects), in order to assess the percentage of cases 
with fatigue in the population that can be attributed to thyroid dysfunction (table 1).1, 2
The attributable risk was 14%, this means that only 14% of the cases of self-reported fatigue in 
the subjects with thyroid dysfunction could be attributed to thyroid dysfunction. The population 
attributable risk was 1%, thus only 1% of the cases of self-reported fatigue in the general 
population could be attributed to thyroid dysfunction.
Table 1. 
A 2 x 2 table with disease frequency (thyroid dysfunction) and outcome (fatigue). 
Fatigue no fatigue
Thyroid dysfunction 39.6% (R
1
) 60.4%
euthyroidism 34.0% (R
0
) 66.0%
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Abstract
objective:  
The aim of this study was to investigate whether thyroid function and thyroid peroxidase 
antibodies (TPOAb) are associated with depression, when using both state and trait parameters 
of depression. 
Method:  
In 1125 participants of the Nijmegen Biomedical Study, thyroid stimulating hormone (TSH), free 
thyroxine (FT
4
) and TPOAb were measured twice. The Beck Depression Inventory (BDI), a self-
reported lifetime diagnosis of depression and the neuroticism scale of the Eysenck Personality 
Questionnaire Revised Short Scale (EPQ-RSS) were used to evaluate the presence of state and 
trait features of depression. 
results:  
We found no association between TSH and FT
4
 levels and BDI score, current depression, lifetime 
diagnosis of depression and EPQ-RSS neuroticism score. Subjects with TPOAb had higher EPQ-
RSS neuroticism scores in comparison to subjects without TPOAb, mean score 4.1 versus 3.2 
(regression coefficient 0.70, 95% CI 0.1-1.3, p-value 0.02 after adjustment for confounders). 
The prevalence of a lifetime diagnosis of depression was higher in subjects with positive TPOAb 
in comparison to participants without TPOAb: 24.2% versus 16.7% (relative risk 1.4, 95% CI 
1.0-2.1, p value 0.04 after adjustment for confounders).
Conclusion:  
TPOAb are positively associated with trait markers of depression. The presence of TPOAb may 
be a vulnerability marker for depression. 
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Introduction
Thyroid dysfunction has been associated with mood disorders.1-5 The general idea is that 
overt hypothyroidism can cause psychiatric diseases like depression, although in patients with 
depression, the incidence of overt thyroid dysfunction is low.2, 4, 6, 7 Previous studies have shown 
a lack of relationship between subclinical or overt hypothyroidism and depression in the general 
population.8-14 
A high-normal FT
4
 and a low-normal TSH were associated with depression in some large 
population studies and a meta-analysis.15-17 This finding is interesting. Within the normal range 
of thyroid function there is an association between serum TSH and FT
4
 levels and several 
pathological conditions. Increased cardiovascular risk, blood pressure, serum cholesterol, body 
mass index and the presence of the metabolic syndrome are associated with a thyroid function 
within the low-normal range.18-23 By contrast, atrial fibrillation is associated with a high-normal 
thyroid function.24 
In the majority of cases, primary hypothyroidism is caused by autoimmune thyroiditis, and in 
these patients thyroid peroxidase autoantibodies (TPOAb) are frequently present. On the other 
hand, TPOAb are detected in 8-18% of the general population.25 The association between 
the presence of TPOAb and depression remains unclear. A large population study found no 
association between the presence of TPOAb and depression, whereas other studies showed 
a positive association between the presence of TPOAb and depression in community based 
samples, cohorts of psychiatric patients and postmenopausal women. An association between 
the presence of TPOAb and a subsequent postpartum depression in pregnant women was also 
shown.10, 26-31
So far, most studies investigating the relationship between thyroid function and depression have 
only focused on state characteristics of depression, i.e. measures of the current presence of 
depressive symptoms. It may be questioned if thyroid function is more distinctly associated with 
trait markers, i.e. markers of long term vulnerability to depression such as lifetime diagnosis of 
depression and neuroticism, a personality trait which is a strong risk factor for depression.32-35 
Aims of the study 
The aim of this study was to investigate whether thyroid function, especially within the 
normal range, and the presence of thyroid peroxidase autoantibodies are associated with the 
prevalence and severity of depression in the general population, when using both state and trait 
markers of depression.
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Subjects and Methods
Study participants 
The subjects of this study are participants of the Nijmegen Biomedical Study (NBS), a large 
population-based survey performed in Nijmegen, a municipality in the eastern part of The 
Netherlands. Details of this study are described before.25 Approval to conduct the study was 
obtained from the Institutional Review Board of the RUNMC. Of each age-group (range 5 years), 
750 men and 750 women were invited to participate. Subjects of 85 years old or older were 
all invited to participate. A total of 22,451 age- and sex-stratified randomly selected adults 
received a questionnaire on lifestyle, medical history and symptoms in 2002-2003, of whom 
9350 adults responded. Of 6343 subjects, blood samples were obtained and TSH and FT
4
 
were measured. The participants, who gave permission for further research, received a second 
questionnaire in 2005-2007. A total of 2253 respondents, in the age group 50 through 70 
years, were invited to participate in a study of non-invasive measurements of atherosclerosis 
(NIMA) of whom 1517 gave their informed consent. In these subjects, blood samples for 
second TSH and FT
4
 measurements and TPOAb measurements were taken between 2005 and 
2008. Baseline and second TSH and FT
4
 measurements were available for 1235 participants. We 
chose to include only the participants of whom two TSH measurements were available. When 
using only one measurement of TSH and FT
4
, the intraindividual variation of TSH and FT
4
 may 
result in an underestimation of the association between thyroid function and depression. For 
our analysis, we excluded subjects with known thyroid disease, those who used thyromimetic 
and/or thyrostatic drugs, and those who had former thyroid surgery and/or radioactive iodine 
treatment. In addition, we also excluded subjects using medication interfering with thyroid 
function such as lithium, amiodarone, kelp, oral glucocorticosteroids and/or dopamine agonists 
because of the possible effect of these medications on thyroid function. A total of 86 women 
and 24 men were excluded.
Laboratory measurements 
Serum TSH was measured by an immunoluminometric assay on a random-access analyzer 
(Architect; Abbott Diagnostics Division). The reference interval used in our laboratory is 0.4-4.0 
mIU/L. Serum FT
4
 was measured with a luminescence enzyme immunoassay on a random-access 
assay system (Vitros ECI; Ortho Clinical Diagnostics). Our laboratory reference interval is 8.0-
22.0 pmol/L. TPOAb were measured with a fluorescence immunoenzymometric assay for the 
quantitative measurement of the IgG class of anti-thyroperoxidase antibodies (AxSYM Anti-TPO; 
Abbott Diagnostics Division). The reference interval was defined as ≤12 kIU/L (data provided by 
manufacturer). More details about these measurements are described elsewhere.25
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Questionnaire 
The first and second questionnaire contained questions about gender, age, weight, height, 
lifestyle, symptoms, medical history including the presence of thyroid disease, depression and 
the use of medication. The presence of a lifetime diagnosis of depression was evaluated by 
the question: "Have you ever needed therapy for a depression, like medication, counseling 
or admission to a psychiatric hospital?” This question was included to detect the presence 
of a lifetime diagnosis of clinical relevant depression. The second questionnaire (filled out in 
2005-2007) contained the Beck Depression Inventory IA (BDI) and the Eysenck Personality 
Questionnaire Revised Short Scale (EPQ-RSS).36-40 
The BDI is a 21-question multiple-choice self-report inventory and one of the most widely used 
instruments for assessing symptoms of depression (alpha coefficient 0.86).37 Participants rated 
the severity of each of the 21 symptoms on a 4-point scale ranging from 0 (symptom not at all 
present) to 3 (symptom severely present). A total score of 63 points is the maximum score. A score 
of 10 points was considered as a cut-off point for the presence of a depression.36 When 1 or 2 
items were missing, the scores of these items were imputed, using the average score of the other 
items of the BDI. When more than 2 items were missing, the total score was regarded as missing. 
Neuroticism (range: 0–12) was measured using the Dutch version of the revised Eysenck 
Personality Questionnaire (EPQ-RSS). Results of the Dutch version of this questionnaire strongly 
resemble those of the English version (alpha coefficient 0.81-0.84).41 The EPQ-RSS is based on 
a three-factor model of personality: neuroticism, extraversion and psychoticism. Neuroticism is 
a stable personality trait that also in later life can be measured reliably as it is not significantly 
affected by physical health variables.42 When 1 or 2 items were missing, the scores of these 
items were imputed, using the average score of the other items of the neuroticism subscale of 
the EPQ-RSS. When more than 2 items were missing, the total score was regarded as missing. 
The maximum score on the neuroticism scale is 12 points.
The BDI score and the presence of depression were considered as state characteristics of 
depression, i.e. measures of the current presence of depressive symptoms. The lifetime 
diagnosis of depression and the EPQ-RSS neuroticism subscale score were studied as trait 
markers, i.e. markers of long-term vulnerability to depression.
Statistical analyses 
For the analyses, we used the mean value of the baseline and second measurements of TSH and 
FT
4
 in order to diminish the underestimation of the association between thyroid function and 
depression due to intraindividual variation of TSH and FT
4
.
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Because of a possible non-linear association between TSH, FT
4
 and depression parameters and a 
skewed distribution of TSH we used tertiles of TSH and FT
4
 within the normal range. Serum TSH 
and FT
4
 levels were divided into 5 subclasses: serum level below the normal range, tertiles of 
serum level within the normal range and serum level above the normal range. Linear regression 
analysis was performed to calculate the regression coefficient (RC) and the 95% confidence 
interval (CI) of the association between the subclasses of TSH and FT
4
, the presence of TPOAb 
and the BDI/EPQ-RSS neuroticism subscale score. Subjects with TSH or FT
4
 within the middle 
tertiles were expected to have the lowest risk of depression and were defined as the reference 
group. To assess relative risks (RR) along with the 95% CI we used loglinear regression analyses 
(Poisson regression with robust standard errors), with the prevalence of current depression or 
lifetime diagnosis of depression as the dependent variable and thyroid function class or the 
presence of TPOAb as the independent variable.43-45 We adjusted all analyses for age, gender 
and body mass index (BMI) because these factors had an influence on both depression and 
thyroid function. Further adjustment for smoking status and co-morbidity like cardiovascular 
disease, cancer, COPD, diabetes mellitus and renal disease did not change results and these 
variables were not included in the model. The chosen level of significance was 5%. We analysed 
the data with STATA version 11.0 (StataCorp, Texas).
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results
The characteristics of the 1125 subjects are shown in Table 1. Women had a higher BDI score, 
a higher EPQ-RSS neuroticism subscale score, a higher prevalence of TPOAb and a higher 
prevalence of a lifetime diagnosis of depression. 
Table 1.  
Characteristics of the study population. 
Characteristic Total 
n=1125
Male 
n=579
Female 
n=546
Age (years)a 56.8 (± 5.7) 57.6 (± 5.7) 56.0 (± 5.6)
BMI (kg/m2)a 25.6 (± 3.6) 26.0 (± 3.2) 25.2 (± 4.0)
TSH (mIU/L) ’02-‘031, b 1.36 (0.98-1.95) 1.37 (0.99-1.91) 1.34 (0.96-2.01)
TSH (mIU/L) ’05-’082, b 1.31 (0.93-1.80) 1.28 (0.91-1.77) 1.34 (0.95-1.83)
FT
4 
(
 
pmol/L)’02-’031, b 13.0 (11.8-14.2) 13.0 (11.7-14.2) 12.9 (11.8-14.2)
FT
4 
(
 
pmol/L) ’05-‘082, b 13.4 (12.1-14.8) 13.3 (12.0-14.6) 13.5 (12.2-14.9)
TPOAb present (%)c  
N=1,124
135 (12.0%) 39 (6.7%) 96 (17.6%)
BDI scorec 5.2 (± 4.7) 4.6 (± 4.6) 5.8 (± 4.8)
BDI score ≥10 (%) 
N=907
143 (15.8%) 64 (14.0%) 79 (17.6%)
EPQ-RSS neuroticism subscale scorec 3.3 (± 2.8) 2.8 (± 2.6) 3.8 (± 2.8)
Lifetime diagnosis of depression (%)c, 
N=1,007
177 (17.6%) 80 (15.7%) 97 (19.5%)
BMI, body mass index; TSH, thyroid stimulating hormone; FT
4
, free thyroxine; TPOAb, thyroid peroxidase antibodies; BDI, 
Beck Depression Inventory 1A; EPQ-RSS, Eysenck Personality Questionnaire Revised Short Scale.
a Mean ± standard deviation 
b Median (interquartile range)  
c   In 1 subject TPOAb was missing, in 218 subjects the BDI score was missing, in 124 subjects the EPQ-RSS neuroticism 
subscale score was missing, in 118 subjects data on lifetime diagnosis of depression were missing.
1 First measurement, 2002-2003
2 Second measurement, 2005-2008
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Table 2 shows the mean BDI scores by TSH and FT
4
 subclasses and by presence of TPOAb. 
Within the normal range, subjects with TSH in the middle tertile and FT
4
 in the lower tertile had 
the lowest BDI score (4.9 and 5.1, respectively). However, the differences in BDI scores were 
only small and there was no significant association found between BDI score and TSH and FT
4
 
subclasses, neither before nor after adjustment for gender, age and BMI, except for subjects 
with FT
4
>22 pmol/l (regression coefficient (RC) 3.5, 95% CI 1.5-5.5, p-value <0.01). Subjects 
without TPOAb had lower BDI scores in comparison to subjects with TPOAb: 5.1 versus 6.0 
respectively (RC 0.96, 95% CI 0.01 to 1.9, p-value 0.05). However, after adjustment for age, 
gender and BMI, there was no difference in BDI scores between these groups. Further analysis 
by gender did not change these results. 
Table 2.  
Mean Beck Depression Inventory 1A (BDI) score by TSH and FT
4 
subclasses and by TPOAb after exclusion of subjects with 
known thyroid disease and the use of interfering medication.
Total numbera BDI score Difference from  
reference group (95% CI)b
TSHc <0.4 mIU/L 10 5.3 0.11 (-2.2 to 2.4)
0.4-1.11 mIU/L 282 5.2 0.22 (-0.6 to 1.0)
1.11-1.62 mIU/Ld 298 4.9 - -
1.62-4.00 mIU/L 294 5.4 0.41 (-0.3 to 1.2)
>4.00 mIU/L 23 5.9 0.82 (-1.4 to 3.0)
FT
4
c <8.0 pmol/L 2 3.0 -2.37 (-6.8 to 2.0)
8-12.4 pmol/L 284 5.1 0.04 (-0.7 to 0.8)
12.4-14.1 pmol/Ld 297 5.2 - -
14.1-22 pmol/L 312 5.3 0.11 (-0.6 to 0.9)
>22 pmol/L 3 8 3.48 (1.5 to 5.5)*
TPOAb ≤ 12 kIU/Ld 791 5.1 - -
> 12 kIU/L 115 6.0 0.74 (-0.2 to 1.7)
BDI, Beck Depression Inventory 1A; TSH, thyroid stimulating hormone; FT
4
, free thyroxine; TPOAb, thyroid peroxidase 
antibodies; CI, confidence interval.
 a  Mean FT
4
 was missing in 11 subjects, TPOAb was missing in 1 subject, the BDI score was missing in 218 subjects. These 
subjects included 2 subjects, with both mean FT
4
 and the BDI score missing.
b  Differences from reference group were obtained from linear regression analyses with adjustment for age, gender and 
body mass index.
c TSH and FT
4
 are mean values of baseline and second measurements. 
d Reference group
* p-value <0.05
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Subjects with a BDI score of ≥10 were considered to have a current depression. Table 3 shows 
the prevalence of current depression by TSH and FT
4
 subclasses and by TPOAb. Subjects with 
TSH and FT
4
 in the middle tertile had the lowest prevalence of depression. However, there was 
no significant association between the subclasses of TSH and FT
4
 or the presence of TPOAb and 
current depression, neither before nor after adjustment for age, gender and BMI. Again, further 
analysis by gender did not change these results.
Table 3.  
Percentage of current depression by TSH and FT
4
 subclasses and by TPOAb after exclusion of subjects with known thyroid 
disease and the use of interfering medication.
Total numbera Current depression 
(%)
relative risk (95% CI)b
TSHc <0.4 mIU/L 10 20.0 1.5 (0.4 to 5.1)
0.4-1.11 mIU/L 282 15.6 1.2 (0.8 to 1.8)
1.11-1.62 mIU/Ld 298 13.1 - -
1.62-4.00 mIU/L 294 17.7 1.3 (0.9 to 2.0)
>4.00 mIU/L 23 26.1 2.0 (0.99 to 4.2)
FT
4
c <8.0 pmol/L 2 0 - -
8-12.4 pmol/L 284 16.6 1.1 (0.8 to 1.6)
12.4-14.1 pmol/Ld 297 15.5 - -
14.1-22 pmol/L 312 15.7 1.0 (0.7 to 1.5)
>22 pmol/L 3 0 - -
TPOAb ≤ 12 kIU/Ld 791 15.3 - -
> 12kIU/L 115 19.1 1.2 (0.8 to 1.9)
TSH, thyroid stimulating hormone; FT
4
, free thyroxine; TPOAb, thyroid peroxidase antibodies; CI, confidence interval.
a  Mean FT
4
 was missing in 11 subjects, TPOAb was missing in 1 subject, the Beck Depression Inventory 1A (BDI) score was 
missing in 218 subjects. These subjects included 2 subjects, with both mean FT
4
 and the BDI score missing.
b Relative risks were obtained from loglinear regression analyses with adjustment for age, gender and body mass index. 
c TSH and FT
4
 are mean values of baseline and second measurements. 
d Reference group
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Table 4 shows the mean EPQ-RSS neuroticism subscale scores by TSH and FT
4
 subclasses and by 
the presence of TPOAb. Within the normal range, subjects in the middle tertile of TSH and FT
4
 
had lower EPQ-RSS neuroticism subscale scores in comparison to the other tertiles. However, 
the difference in EPQ-RSS neuroticism subscale score between the groups was only small and 
no significant association between the subclasses of TSH and FT
4
 and the EPQ-RSS neuroticism 
subscale score was found, neither before nor after adjustment for gender, age and BMI. 
Subjects with TPOAb had higher EPQ-RSS neuroticism subscale scores in comparison to subjects 
without TPOAb, 4.1 versus 3.2 respectively (RC 0.70, 95% CI 0.1 to 1.3, p-value 0.02 after 
adjustment for age, gender and BMI). Because women were more frequently positive for TPOAb 
and had higher EPQ-RSS neuroticism subscale scores, gender could be a major confounder. 
Therefore, analyses by gender were performed. Men with positive TPOAb had higher EPQ-
RSS neuroticism subscale scores in comparison to men without TPOAb: 4.3 versus 2.7 
respectively (RC 1.6, 95% CI 0.4 to 2.7, p-value <0.01 after adjustment for age and BMI). The 
results remained similar after exclusion of men with TSH or FT
4
 outside the normal range. For 
women, no association between TPOAb and EPQ-RSS neuroticism subscale scores was found: 
women with positive TPOAb had only a slightly higher EPQ-RSS neuroticism subscale score in 
comparison to women without TPOAb: 4.0 versus 3.7, but this difference was not statistically 
significant, neither before nor after adjusment for confounders (RC 0.29, 95% CI -0.4 to 1.0, 
p-value 0.41 after adjustment for age and BMI). 
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Table 4.  
Mean EPQ-RSS neuroticism subscale score by TSH and FT
4
 subclasses and by TPOAb after exclusion of subjects with 
known thyroid disease and the use of interfering medication.
Total numbera ePQ-rSS subscale 
score
Difference from reference 
group (95% CI)b
TSHc <0.4 mIU/L 11 3 -0.26 (-1.2 to 0.7)
0.4-1.11 mIU/L 321 3.2 0.05 (-0.4 to 0.5)
1.11-1.62 mIU/Ld 328 3.1 - -
1.62-4.00 mIU/L 318 3.5 0.36 (-0.1 to 0.8)
>4.00 mIU/L 23 4.0 0.80 (-0.4 to 2.0)
FT
4
c <8.0 pmol/L 3 4.3 1.30 (-1.2 to 3.8)
8-12.4 pmol/L 317 3.3 0.15 (-0.3 to 0.6)
12.4-14.1 pmol/Ld 325 3.2 - -
14.1-22 pmol/L 341 3.3 0.05 (-0.4 to 0.5)
>22 pmol/L 4 4.8 3.03 (-1.5 to 7.6)
TPOAb ≤ 12 kIU/Ld 879 3.2 - -
> 12 kIU/L 121 4.1 0.70 (0.1 to 1.3)*
TSH, thyroid stimulating hormone; FT
4
, free thyroxine; TPOAb, thyroid peroxidase antibodies; EPQ-RSS, Eysenck Personality 
Questionnaire Revised Short Scale; CI, confidence interval.
a  Mean FT
4
 was missing in 11 subjects, TPOAb was missing in 1 subject, the EPQ-RSS neuroticism scale score was missing in 
124 subjects. 
b  Differences from reference group were obtained from linear regression analyses with adjustment for age, gender and 
body mass index. 
c TSH and FT
4
 are mean values of baseline and second measurements. 
d Reference group. 
*p-value <0.05
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Table 5 shows the prevalence of a lifetime diagnosis of depression by TSH and FT
4
 subclasses 
and by presence of TPOAb. No association was found between the subclasses of TSH and FT
4
 
and lifetime diagnosis of depression, except for a higher prevalence of lifetime diagnosis of 
depression in subjects with FT
4
 >22 pmol/L in comparison to subjects in the middle tertile of 
FT
4
, 66.7% versus 19.0% (RR 4.6, 95% CI 1.9 to 11.3, p value <0.01). There was a positive 
association between the presence of TPOAb and the prevalence of a lifetime diagnosis of 
depression: the prevalence of lifetime diagnosis of depression was 24.2% in subjects with 
TPOAb versus 16.7% in subjects without TPOAb (RR 1.4, 95% CI 1.0 to 2.1, p value 0.04 after 
adjustment for age, gender and BMI). Further analyses by gender gave similar results for both 
men and women.
Table 5.  
Percentage of lifetime diagnosis of depression by TSH and FT
4
 subclasses and by TPOAb after exclusion of subjects with 
known thyroid disease and the use of interfering medication.
Total numbera Lifetime depres-
sion (%)
relative risk 
(95% CI)b
TSHc <0.4 mIU/L 11 9.1 0.6 (0.1 to 3.8)
0.4-1.11 mIU/L 323 16.4 1.0 (0.7 to 1.4)
1.11-1.62 mIU/Ld 329 16.4 - -
1.62-4.00 mIU/L 320 20.0 1.2 (0.8 to 1.6)
>4.00 mIU/L 24 20.8 1.3 (0.6 to 3.0)
FT
4
c <8.0 pmol/L 3 33.3 1.8 (0.5 to 6.2)
8-12.4 pmol/L 320 18.1 1.0 (0.7 to 1.4)
12.4-14.1 pmol/Ld 327 19.0 - -
14.1-22 pmol/L 343 15.5 0.9 (0.6 to 1.2)
>22 pmol/L 3 66.7 4.6 (1.9 to 11.3)*
TPOAbc ≤ 12 kIU/Ld 882 16.7 - -
> 12kIU/L 124 24.2 1.4 (1.0 to 2.1)*
TSH, thyroid stimulating hormone; FT
4
, free thyroxine; TPOAb, thyroid peroxidase antibodies; CI, confidence interval.
a  Mean FT
4
 was missing in 11 subjects, TPOAb was missing in 1 subject, data on lifetime diagnosis of depression were 
missing in 118 subjects. 
b Relative risks were obtained from loglinear regression analyses with adjustment for age, gender and body mass index. 
c TSH and FT
4
 are mean values of baseline and second measurements. 
d Reference Group
* p-value <0.05
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Discussion
In our population-based study, we found no association between thyroid function and state 
or trait factors of depression. There were only few subjects with a mean value of TSH or FT
4
 
outside the normal range, so analyses of those subclasses of TSH and FT
4
 should be interpreted 
with caution.
Our results are in line with a number of previous studies, including a large population study 
with 30,000 participants, performed in Norway in 1995 (the HUNT-study), which also found 
no association between thyroid function classes and depression after adjustment for gender 
and age.8-12 In contrast to these studies, several other studies suggested that a FT
4
 level in the 
upper-normal range and a TSH level in the low-normal range are associated with an increased 
risk of depression.15-17 We could not confirm these results. It is difficult to compare these 
studies because of their different study designs. In the various studies, the composition of the 
population differed considerably. Some studies included only male subjects
 
or
 
young adults, 
whereas our study had a restrictive age range of 50 to 70 years. Some studies used a clinical 
sample instead of a population based sample. Also, the studies used different clinical tests or no 
validated test at all to assess the presence of depression.
Because the course of symptoms of depression has been shown to be variable, we hypothesized 
that trait markers for depression, like the personality trait neuroticism and a lifetime diagnosis 
of depression, might be more distinctly associated with thyroid function than state factors. In 
our study, we found no association between thyroid function and these trait markers. There 
are only few studies that have studied the relationship between thyroid function and trait 
markers instead of state markers of depression and these studies yielded conflicting results. In 
accordance with our results, Forman et al. found no association between lifetime diagnosis of 
depression and thyroid function.15 Frey et al found that low TSH levels in 121 healthy subjects 
were associated with neuroticism.46 Perhaps the differences in results can be explained by the 
differences in study populations. For example, Frey et al. recruited mostly young volunteers in 
comparison to the population-based sample, aged between 50 and 70 years, in the present 
study. Also, Frey et al. used a different kind of instrument to evaluate neuroticism (NEO Five-
Factor Inventory).
Some previous studies have reported a higher prevalence of TPOAb in patients with mood 
disorders or a positive association between the presence of TPOAb and depression.10, 28, 29, 31 
These studies comprised small sample sizes of selected groups of subjects, such as pregnant 
women, perimenopausal women and psychiatric patients. We did not find a significant 
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relationship between the presence of TPOAb and state markers of depression in the general 
population. Our results are concordant with another large population based study, which 
showed no relationship between the presence of TPOAb and state markers of depression.27
However, we did find an association between the presence of TPOAb and trait factors like 
neuroticism and lifetime diagnosis of depression. To our knowledge, this is the first study 
examining the relationship between the presence of TPOAb and neuroticism. Carta et al. also 
found an association between the presence of a lifetime diagnosis of mood or anxiety disorder 
and TPOAb in both men and women.26 A history of bipolar disorder can also be regarded as a 
trait characteristic, because it represents lifetime vulnerability. Previous studies have reported a 
higher prevalence of positive TPOAb in patients with a bipolar disorder.47 Vonk et al. concluded 
from a twin study that autoimmune thyroiditis is not only related to bipolar disorder itself but 
also to the genetic vulnerability to develop this disorder, whereas Hillegers et al. found bipolar 
offspring to be more vulnerable to develop thyroid autoimmunity independently from the 
vulnerability to develop psychiatric disorders.48, 49 This study showed that the presence of TPOAb 
is associated with trait characteristics of depression, whereas thyroid function is not. This finding 
suggests that the higher prevalence of current thyroid dysfunction in subjects with TPOAb is not 
the cause of the association between TPOAb and trait characteristics of depression.25 However, 
as neuroticism and life time depression are trait characteristics, an association between thyroid 
dysfunction and depression may have been present in the past. Alternatively, we hypothesize 
that the association between TPOAb and trait characteristics of depression does not reflect 
a causal relationship but more likely is the result of a co-association with another factor, like 
predisposition for auto-immunity. 
The strength of our study is that we measured thyroid function twice. Most of the reported 
associations between thyroid function and depression in population-based studies are based on 
one single measurement of TSH and/or FT
4
. These associations might be underestimated due 
to the intraindividual variation of the TSH and FT
4
 measurements. Other strengths of our study 
are the fact that we measured both trait and state characteristics of depression and the large 
sample size.
Our study has some limitations. As already mentioned, there were only few subjects with a 
mean value of TSH or FT
4
 outside the normal range, so analyses of those subclasses of TSH 
and FT
4
 should be interpreted cautiously. Second, the BDI has been validated as an excellent 
screening instrument for the presence of depression.36-38 However, budget constraints did not 
permit us to perform a clinical evaluation to diagnose a depression. Third, due to the nature of 
the NIMA study, our study population comprised only subjects between 50 and 70 years of age. 
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Further studies will have to confirm our results in other age groups. Finally, we cannot rule out 
selection bias due to a difference in depression or thyroid function among the responders versus 
non-responders. 
In conclusion, we found no association between thyroid function and the state and trait 
markers of depression. The presence of TPOAb was not associated with state markers but had 
a positive association with trait markers of depression. We therefore conclude that the presence 
of TPOAb may be a vulnerability marker for depression.
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Abstract
objective  
The aim of this study was to investigate the influence of age on the association between thyroid 
function and mortality.
Design  
The Nijmegen Biomedical Study is a population-based study comprising 5816 randomly selected 
adults of all age groups without previously known thyroid disease.
Methods  
Thyroid stimulating hormone (TSH), free thyroxine (FT
4
) and peroxidase antibodies were 
measured in 2002-2003. The number of deaths were established in 2012 (median follow up 
time 9.4 years). 
results  
Subclinical thyrotoxicosis was associated with mortality in subjects < 65 years old (HR 2.5, 95% 
CI 1.1-5.7), but not in subjects > 65 years old. As for thyroid function within the normal range: 
in the 493 participants aged 80 years or older, a FT
4
 level in the high-normal range (18.5-22 
pmol/l) was associated with a higher mortality in comparison to FT
4
 levels in the middle range 
(11.5-15.0 pmol/L): HR 1.7 (95% CI 1.0-2.9). In these elderly, also TSH levels within the high-
normal range (3.0-4.0 mIU/L) were associated with a higher mortality in comparison to TSH 
levels within the middle range (1.0-2.0 mIU/L): HR 1.8 (95% CI 1.0-3.1). 
Conclusions  
The relationship between thyroid function and mortality differs according to age. This finding 
might (partially) explain the discrepant results of previous studies examining the relationship 
between thyroid function and mortality in different age groups. 
73
Introduction
Thyroid function disorders are common in the general population. The prevalence varies 
among different populations, depending on the iodine intake of the population. Overt thyroid 
dysfunction is associated with several cardiovascular risk factors, morbidity and mortality.1, 
2 Subclinical thyroid function disorders are also associated with cardiovascular risk factors 
and cardiovascular diseases, although the associations are generally less strong and more 
controversial due to conflicting results in numerous studies.3, 4 Whether subclinical thyroid 
dysfunction is associated with mortality remains controversial with some studies finding 
an association between mortality and subclinical hypothyroidism5-10 and/or subclinical 
hyperthyroidism,7 while other studies do not confirm these results.11-15 Recently 6 meta-analyses 
reported conflicting results. These studies had to deal with clinical heterogeneity among the 
studies due to differences in both the included populations and methods of adjustment for 
confounders.16-21
In the past few years, the effects of thyroid function within the reference range on various 
biological parameters have been studied.22 Only few studies investigated the relationship 
between thyroid function within the normal range and mortality. These studies also reported 
conflicting results.23-29 Some found a positive association between mortality and blood 
TSH concentration within the normal range,23 whereas others found a negative24, 28 or no 
association.25-27, 29 In addition, a positive association between mortality and FT
4
 within the 
normal range has been reported in elderly.24, 27, 29
These latter studies suggest that age might influence the association between thyroid function 
and mortality. However, the total number of young participants and oldest elderly is limited 
in most studies. Some studies, including 2 meta-analyses, found an association between 
subclinical thyroid dysfunction and mortality in younger, but not in older subjects.9, 17, 18 
Furthermore, the results of the Leiden 85+ Study suggest a protective effect of higher TSH 
levels in the oldest elderly.24 Other studies could not confirm this effect, but they did show 
a beneficial effect of lower FT
4
 levels, even within the normal range, in the elderly.27, 29 Most 
studies have been performed in iodine sufficient populations, in which TSH increases with age. 
In populations with a (mild) iodine insufficiency at present or in the past, TSH decreases with 
age and FT
4
 increases with age.30,32
The aim of this study was to investigate the influence of age on the association between thyroid 
function and mortality, in a population in which TSH decreases and FT
4
 increases with age. 
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Materials and Methods
Study participants 
The subjects of this study are participants of the Nijmegen Biomedical Study (NBS), a large 
population-based survey performed in 2002-2003 in Nijmegen, a municipality in the eastern 
part of The Netherlands. Details of this study have been described before.30 In the past, mild 
iodine deficiency was present in this part of the Netherlands.33, 34 Currently, the iodine status 
of this population is considered to be adequate.35, 36 Approval to conduct the study was 
obtained from the Institutional Review Board. A total of 22,451 age- and sex-stratified randomly 
selected adults received a questionnaire on gender, age, weight, height, lifestyle, medical 
history and the use of medication. Of each 5-year age-group, 750 men and 750 women were 
invited to participate. We excluded the subjects with known thyroid disease (overt/subclinical 
thyrotoxicosis or hypothyroidism), those who used thyromimetic and/or thyrostatic drugs, and 
those who had former thyroid surgery and/or radioactive iodine treatment. Also, participants 
who were pregnant or used medication interfering with thyroid function such as lithium, 
amiodarone, oral glucocorticosteroids, kelp, dopamine agonists and/or opiates were excluded 
because of the possible influence of pregnancy and these medications on serum TSH and FT
4
 
levels. 
Data on vital status and changes in address were obtained from the municipal registers at set 
times. For respondents who died, the date of death was traced through death certificates from 
municipal registers until October, 2012. When subjects moved out of the region and no data on 
vital status could be obtained anymore, data were used for analyses until the date of moving 
out (interval censuring). 
Laboratory methods 
Blood samples were taken in 2002-2003 in order to measure thyroid stimulating hormone 
(TSH), free thyroxine (FT
4
) and peroxidase antibodies. Serum TSH was measured by an 
immunoluminometric assay on a random-access analyzer (Architect; Abbott Diagnostics 
Division). The reference interval used in our laboratory is 0.4-4.0 mIU/L. Serum FT
4
 was 
measured with a luminescence enzyme immunoassay on a random-access assay system 
(Vitros ECI; Ortho Clinical Diagnostics). Our laboratory reference interval is 8.0-22.0 pmol/L. 
TPOAbs were measured with a fluorescence immunoenzymometric assay for the quantitative 
measurement of the IgG class of anti-thyroperoxidase antibodies (AxSYM Anti-TPO; Abbott 
Diagnostics Division). The reference interval was defined as <12 kIU/L (data provided by 
manufacturer). Thyroid function was classified as overt thyrotoxicosis if TSH was <0.4 mIU/L and 
FT
4 
was >22 pmol/L and it was classified as subclinical thyrotoxicosis if TSH was <0.4 mIU/L and 
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FT
4
 was ≥8 pmol/L and ≤ 22 pmol/L. Thyroid function was classified as overt hypothyroidism if 
TSH was >4.0 mIU/L and FT
4
 was <8 pmol/L and as subclinical hypothyroidism if TSH was >4.0 
mIU/L and FT
4
 was ≥8 pmol/L and ≤ 22 pmol/L. When both TSH and FT
4
 were within the normal 
range, thyroid function was classified as euthyroidism. When either TSH or FT
4
 was not within 
the normal range, thyroid function was classified as thyroid dysfunction.
Statistical analyses  
We produced Kaplan-Meier curves to compare unadjusted survival ratios of participants 
according to the thyroid function class and according to subclasses of TSH and FT
4
 within the 
normal range. For this purpose, we stratified the euthyroid participants according to the TSH 
level (TSH 0.4-1.0, 1.0-2.0, 2.0-3.0, 3.0-4.0 mIU/L) and FT
4
 level (8.0-11.5, 11.5-15.0, 15.0-
18.5, 18.5-22.0 pmol/L). 
Using a Cox proportional hazards model, we calculated adjusted hazard ratios (HR) with a 
95% confidence interval (CI) of mortality by thyroid function classes, using the euthyroid 
group as the reference group. In addition, we calculated adjusted hazard ratios (HR) with a 
95% confidence interval (CI) of mortality of the TSH and FT
4
 subclasses within the normal 
range in euthyroid subjects. We adjusted all analyses for possible confounders, selecting the 
following factors for adjustment because of their known or presumed relation with both thyroid 
function and mortality: age, gender, body mass index (BMI), smoking status, medical history 
of hypertension, hypercholesterolemia, diabetes mellitus, cardiovascular disease, cancer, deep 
venous thrombosis, asthma/COPD, rheumatoid arthritis, renal and/or liver disease. Log minus 
log plots and inclusion of time dependent covariates in the Cox model were used to check the 
proportional hazards model assumption, which was not violated in any of the models. To assess 
the influence of age on the relationship between mortality and thyroid function, we subdivided 
the participants into three age groups: age < 65 years, age 65-80 years and age ≥ 80 years old 
and performed the analyses as described above in each subgroup. All statistical analyses were 
performed using STATA version 11 (StataCorp, Texas).
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results 
A total of 9350 subjects responded to the invitation to fill out the questionnaire (response rate: 
42%). Of these responders, 6434 (69%) subjects gave permission for blood withdrawal. The 
demographic characteristics of the non-responders differed only slightly from the responders, 
who gave permission for blood withdrawal: the mean age was 53.1 versus 56.1 years 
respectively, the percentage of women was 50.2% versus 53.8%. We excluded 47 pregnant 
women and 212 subjects using medication interfering with thyroid function. In addition, we 
excluded 322 subjects because of previously known thyroid disease. Of 37 subjects, the date 
of blood collection was missing or the follow up was completely missing and they were also 
excluded. The median follow up time was 9.4 years. Of the remaining 5816 participants, 775 
subjects (13.3%) died within the follow up period of the study. Table 1 shows the population 
characteristics. Data on BMI were missing in 137 subjects, data on smoking status were missing 
in 17 subjects and data on medical history were missing in 54 subjects.
The Kaplan-Meier survival curves for different thyroid categories are depicted in figure 1. The 
lowest survival rates were observed in subjects with thyrotoxicosis. Subclinical thyrotoxicosis was 
also associated with lower survival rates, especially in subjects < 65 years old. The Kaplan-Meier 
survival curves for TSH and FT4 subclasses in euthyroid subjects are shown in figure 2 and 3. 
Subjects with a high-normal FT
4
 level (18.5-22.0 pmol/L) had the lowest survival rates in subjects 
≥ 65 years old but no difference in survival rates between FT
4
 subclasses was found in subjects 
<65 years old. 
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Table 1.  
Characteristics of the population. 
Characteristic Total 
n=5816
Age < 65 years 
n=3773
Age 65-80 years 
n=1550
Age ≥ 80 years 
n=493
Number of deaths 775 (13.3%) 110 (2.9%) 362 (23.4%) 303 (61.5%)
Age (years)a 55.7 ± 17.9 45.3 ± 12.9 71.9 ±4.3 84.0 ±3.1
Male 2761 (47.5%) 1611 (42.7%) 875 (56.5%) 275 (55.8%)
BMI (kg/m2)a 25.1 ± 4.0 24.8 ± 4.2 25.9 ± 3.7 25.2 ±3.8
Smoking no. (%) 1301 (22.4%) 1004 (26.7%) 241 (15.6%) 56 (11.4%)
Medical history of:
- COPD/asthma (%) 712 (12.4%) 443 (11.8%) 203 (13.3%) 66 (13.6%)
- CVD (%) 577 (10.0%) 133 (3.6%) 312 (20.4%) 132 (27.1%)
- rheumatic disease (%) 482 (8.4%) 192 (5.1%) 220 (14.4%) 70 (14.4%)
- cancer (%) 446 (7.7%) 162 (4.3%) 200 (13.1%) 84 (17.3%)
- diabetes mellitus (%) 315 (5.5%) 110 (2.9%) 154 (10.1%) 51 (10.5%)
- hypertension (%) 1365 (25.5%) 649 (18.0%) 547 (40.9%) 169 (41.5%)
- hypercholesterolemia (%) 899 (17.1%) 407 (11.4%) 429 (33.0%) 63 (17.0%)
- VTE (%) 221 (3.8%) 66 (1.8%) 99 (6.5%) 56 (11.5%)
- kidney disease (%) 171 (3.0%) 85 (2.3%) 51 (3.3%) 35 (7.1%)
- liver disease (%) 134 (2.3%) 89 (2.4%) 35 (2.3%) 10 (2.1%)
TPOAbs positive 735 (12.6%) 448 (11.9%) 234 (15.1%) 53 (10.8%)
TSH (mIU/L)b 1.34 (0.34-4.92) 1.41 (0.43-4.72) 1.24 (0.26-5.58) 1.15 (0.21-5.68)
FT
4 
(
 
pmol/L)b 13.3 (9.7-18.2) 13.0 (9.4-17.4) 13.6 (9.9-19.0) 14.3 (10.3-19.3)
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; VTE, venous  
thromboembolism; TPOAbs, peroxidase antibodies; TSH, thyroid stimulating hormone; FT
4
, free thyroxine.
a Plus-minus values are means ± standard deviations; 
b Geometric mean, 2.5th-97.5th percentiles. 
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number at risk
Thyrotoxicosis 9 9 8 6 5
Subcl. thyrotoxicosis 193 176 164 146 129
Euthyroidism 5365 5084 4693 4347 4044
Subcl. hypothyroidism 212 197 183 174 157
Hypothyroidism 22 20 20 17 15
number at risk
Thyrotoxicosis 5 5 5 4 4
Subcl. thyrotoxicosis 72 66 66 60 57
Euthyroidism 3547 3365 3145 2963 2846
Subcl. hypothyroidism 125 115 111 106 101
Hypothyroidism 15 15 15 12 11
Figure 1  
Kaplan-Meier survival curves by thyroid function class, stratified for age.
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Figure 2  
Kaplan-Meier survival curves by TSH subclass in euthyroid subjects, stratified for age.
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Figure 3  
Kaplan-Meier survival curves by FT
4
 subclass in euthyroid subjects, stratified for age. 
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Table 2 shows the number of deaths within the follow up period and the hazard ratios by 
thyroid function class, stratified for age and adjusted for possible confounders. Seven subjects 
had a serum TSH >0.4 mIU/L and FT
4
 >22 pmol/L, 8 subjects had a serum TSH value of <0.4 
mIU/L and FT
4
 <8 pmol/L and were not assigned to one of the thyroid function classes. They 
were assigned to the thyroid dysfunction group. Thyroid dysfunction (either TSH or FT
4
 not 
within the normal range) was associated with a higher mortality in comparison to euthyroidism, 
21.3 versus 12.7%, HR 1.3 (95% CI 1.0-1.6) after adjustment for possible confounders. The 
difference was more distinct in subjects < 65 years old: 5.3% versus 2.8%, HR 1.7 (95% CI 0.9-
3.2). The results of subjects with overt hypothyroidism and thyrotoxicosis should be interpreted 
cautiously, as only a limited number of participants were found to have an overt thyroid 
dysfunction. Mortality was higher in subjects with overt thyrotoxicosis in comparison to subjects 
with euthyroidism, 55.6% versus 12.7%, HR 8.2 (95% CI 3.4-19.7). Subclinical thyrotoxicosis 
was only associated with mortality in subjects < 65 years old, 9.7% versus 2.8% (HR 2.5 (95% 
CI 1.1-5.7), but not in subjects aged 65 years or older.
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Table 3 shows the number of deaths and the hazard ratios in euthyroid subjects by TSH and FT
4
 
subclasses within the normal range. A FT
4
 level in the high-normal range (18.5-22 pmol/l) was 
associated with a higher mortality in comparison to FT
4
 levels in the middle range (11.5-15.0 
pmol/L): 39.3% versus 11.0%, HR 1.6 (95% CI 1.1-2.4). Sub analysis by age showed that this 
association was only present in subjects ≥ 80 years old (HR 1.7 (95% CI 1.0-2.8)). TSH levels 
within the high-normal range (TSH 3.0-4.0 mIU/L) were associated with a higher mortality in 
comparison to TSH levels in the middle range (1.0-2.0 mIU/L) in subjects >80 years old: 83.3 % 
versus 57.4 %, HR 1.8 (95% CI 1.0-3.1) which was not the case in subjects <80 years old.
There was no association between the presence of TPOAbs and mortality in the total population 
(HR 0.9, 95% CI 0.7-1.2) nor in the different age groups (data not shown).
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Discussion
This large population-based study, comprising randomly selected adults of all age groups, 
provided the opportunity to investigate the influence of age on the relationship between 
thyroid function and mortality in a population in which TSH decreases and FT
4
 increases with 
age.30 
Regarding the relationship between thyroid function in euthyroid subjects and mortality, the 
association between higher FT
4
 levels within the normal range and mortality was only present 
in the oldest participants. These findings are similar to the results of the Leiden 85+ study, 
the studies of Waring et al. and Van der Beld et al.24, 27, 29 The reason why higher FT
4
 but not 
lower TSH levels within the normal range predict mortality in this oldest group is not clear. As 
previously hypothesized, these results might suggest that there is a change of pituitary TSH set 
point in elderly, e.g. an altered pituitary sensitivity for thyroid hormones, and higher FT
4
 levels 
do not cause the same TSH suppression as in younger individuals. Another explanation could 
be that higher FT
4
 levels reflect a decreased 5’-deiodination due to non-thyroidal illness and 
are associated with lower T
3
 levels. However, as shown by Waring et al. and in the Leiden 85+ 
Study, the relationship between FT
4
 and mortality seems to be independent of the T
3
 level.24, 29 
In our study, all the euthyroid subjects >80 years old with a FT
4
 level of 18.5-22.0 pmol/L had a 
TSH level < 2.0 mIU/L. These subjects comprised only a small subset of the subjects with a TSH 
level < 2.0 mE/L. The majority of the subjects in this oldest group with a low-normal TSH had a 
low- or middle-normal FT
4
 (8-18.5 pmol/L) and those subjects did not have a higher mortality. 
Therefore, FT
4
 seems to be
 
a better marker to predict mortality in elderly than TSH. On the other 
hand, a high-normal TSH but not a low-normal FT
4
 level was also associated with mortality 
in elderly. Our study was a cross sectional survey and no causal relationships can be shown. 
Prospective intervention trials are needed to assess the targets for treatment in this subgroup. 
Our study provides new insights for the ongoing debate about the upper limit of the reference 
range of TSH, especially in elderly. It has been suggested to increase the upper limit in elderly.37, 
38 Arguments for this recommendation are the increase of TSH with age in several (iodine 
sufficient) populations and the high amount of older, TPOAbs negative subjects with TSH above 
the upper limit of the currently used reference range.29, 38, 39. However, in our population TSH 
decreases and FT
4
 increases with age probably due to mild iodine insufficiency in the past, 
leading to autonomous function of the thyroid (despite the adequate iodine status at present, 
achieved after increasing the amount of iodized salt in bakeries in 1982).30, 40 Moreover, in our 
population, a high-normal TSH level was associated with mortality in elderly. So, the suggestion 
of increasing the upper limit of the reference range of TSH in elderly seems not appropriate 
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for our population. Reference ranges might be different not only for different races or ages, 
as previously suggested
,
 but also for different populations. On the other hand, despite the 
fact that an increase of FT
4
 with age appears to be ‘normal’ in our population (when using the 
population distribution to assess what is normal), we found that in elderly a higher FT
4
 within 
the normal range was associated with mortality. This implicates that one should not only use 
the population distribution but also the clinical consequences of thyroid hormones levels to 
determine the reference ranges. 
We found inconclusive and conflicting results regarding the relationship between TSH within 
the normal range and mortality in subjects aged 65-80 years old. These results do not seem to 
make sense from a biological point of view and it is possible that some of the significant results 
might be due to chance due to multiple testing. These findings reflect the discrepant results 
of previous studies investigating the relationship between thyroid function and mortality and 
endorse the current controversy regarding this topic. 
As inevitable in a population based study, the number of subjects with subclinical and overt 
thyroid dysfunction was limited. Despite the small number of participants with subclinical 
thyrotoxicosis (n=193), we observed an association between subclinical thyrotoxicosis and 
mortality in younger subjects only, not in participants ≥ 65 years old. An explanation for 
this finding could be the fact that in older subjects there is a larger contribution of other 
cardiovascular risk factors, like age, and that there is more competing mortality (independent of 
thyroid function).
Similar to these results, meta analyses by Ochs et al. and Ravzi et al. reported no association 
between mortality and subclinical hypothyroidism in the total population, but they did find an 
association between subclinical hypothyroidism and mortality in younger participants (age <65 
years).17, 18 We could not detect a significant relationship between subclinical hypothyroidism 
and mortality. We cannot exclude that we had too limited power for this subgroup to show a 
modest relationship with mortality. Recently 6 meta-analyses regarding the relationship between 
thyroid function class and mortality reported conflicting results. Völzke et al. concluded that 
the current available evidence for a causal relation of thyroid dysfunction and mortality is 
weak due to highly discrepant results of previous studies, probably due to confounding and 
selection bias.21 Singh et al. and Rodondi et al. found an association between cardiovascular 
mortality and subclinical hypothyroidism,19, 20 whereas Haentjes et al. only found an association 
between subclinical hyperthyroidism and all cause mortality.16 Ochs et al. and Ravzi et al. found 
no association between mortality and subclinical hypothyroidism in the total population, but 
they did find an association between subclinical hypothyroidism and mortality in younger 
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participants (age <65 years).17, 18 These discordant results might be caused by varying methods 
of adjustment for confounders and the clinical heterogeneity among the studies due to 
differences in populations. As we have shown in this study, the age of the study participants 
can be of major influence on the outcome of the study and therefore might be one factor 
explaining the discrepancies between the studies.
Our study has a few limitations. We did not measure T
3
, so we might have missed some cases 
of overt thyrotoxicosis in subjects with normal FT
4
 and elevated T
3
 and misclassified those 
subjects as having a subclinical thyrotoxicosis. Second, analyses were based on one single 
measurement of TSH and FT
4
. Due to the variation of TSH and FT
4
, the relationship between 
thyroid function and mortality might be underestimated as a result of regression dilution bias.41 
In addition, transient thyroid abnormality such as thyroiditis may have been misclassified. Third, 
at baseline we excluded subjects with known thyroid disease and those who used thyromimetic 
and/or thyrostatic drugs. However, we did not assess whether treatment with thyrostatic or 
thyromimetic drugs was started during follow up. Finally, we had no data on the causes of 
death so we could not perform cause specific mortality analysis.
In conclusion, age influences the relationship between thyroid function and mortality. 
Subclinical thyrotoxicosis was associated with mortality in younger subjects only. In elderly, 
within the normal range of thyroid function, both high-normal FT
4
 and high-normal TSH levels 
were associated with mortality. The fact that previous studies comprised specific and different 
age groups, can, at least in part, explain the discrepant findings and the remaining controversy 
concerning the relationship between thyroid function and mortality. 
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Abstract
Introduction  
Thyroid dysfunction is associated with several diseases and mortality. Due to the within-
individual variation of TSH and FT
4
 levels, the association between thyroid function and disease 
or mortality rates might be underestimated in studies based on one single measurement of 
TSH and/or FT
4
. This kind of bias is called regression dilution bias. The aim of this study was 
to examine the within-individual variability of TSH and FT
4
 measurements several years apart 
in different study cohorts and to determine the magnitude of the underestimation of the 
association between thyroid function and disease rates in population based studies using only 
one baseline measurement. 
Methods 
We used a pair of measurements of serum TSH and FT
4
 levels of subjects of the Nijmegen 
Biomedical Study (NBS) and the Rotterdam Study (RS) to calculate the regression dilution 
ratio (RDR) with a nonparametric method, the Macmahon’s method. Risk estimates could be 
corrected for regression dilution bias by dividing them by the RDR.   
results 
The RDRs of serum TSH in the NBS and RS were 0.74 and 0.78, respectively. The RDRs of serum 
TSH were similar for women and men, 0.75 and 0.74 in the NBS and 0.80 and 0.77 in the RS. 
The RDR of serum FT
4
 in subjects in the NBS was 0.77. 
Conclusion  
The relationship between thyroid function and disease rates is underestimated by studies using 
only one measurement of TSH and FT
4
. The true association will be about 33% (1/0.75) higher 
for studies with a follow-up time of 2-4 years.
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Introduction
Thyroid dysfunction is associated with several diseases, such as atrial fibrillation and 
cardiovascular disease, and with mortality.1, 2 Most of the reported associations between 
thyroid function and disease or mortality rates in population-based studies are based on one 
single measurement of TSH and/or FT
4
. These associations might be underestimated due to the 
intraindividual variation of the TSH and FT
4
 measurements, which will especially be the case in 
studies with a long follow up period. This kind of bias is called regression dilution bias.3-6
The overall variation of the thyroid function measurement consists of several components. 
The preanalytical variation comprises the circumstances of blood withdrawal, like the time of 
the day, the use of tourniquet, whether the subject is fasting or rested or not. The analytical 
variation is another cause of variation but is expected to be smaller in comparison to the 
biological variation. The biological variation is caused by circadian variation, seasonal variation 
and other factors like change of age, weight, diet, smoking, pregnancy, medication and co-
morbidity.7-10
The aim of this study was to examine the within-individual variability of TSH and FT
4
 
measurements several years apart in different study cohorts and to determine the magnitude 
of the underestimation of the association between thyroid function and disease rates in 
population-based studies using only one baseline measurement. In addition, we will illustrate 
this using an example.  
Subjects and laboratory results 
Subjects included in this study were derived from 2 large population-based studies. Approval 
to conduct the studies was obtained from the Institutional Review Board. We excluded the 
subjects with previously known thyroid disease, thyroid surgery, iodine treatment and/or the use 
of thyroid hormones or thyrostatic drugs in order to assess the variability of the thyroid function 
itself instead of the influence of thyrostatic and/or thyromimetic drugs or the clinical course of 
thyroid disease.
Participants of the Nijmegen Biomedical Study (NBS), a population-based survey performed in 
the eastern part of the Netherlands, are randomly selected, for age and sex stratified adults. 
From September 2002 until November 2003 non-fasting blood samples of 6434 subjects were 
taken. More details about this study are described elsewhere.11 In 2005, subjects in the age 
group 50 through 70 years (N=2253) were invited to participate in a study on atherosclerosis. 
Of this subset of participants, 1161 subjects of the subjects consented and blood samples for 
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second TSH and FT
4
 measurements were taken between June 2006 and April 2008. A total 
of 371 subjects were excluded because of previously known thyroid disease. Serum TSH was 
measured by an immunoluminometric assay on a random-access analyzer (Architect; Abbott 
Diagnostics Division). The reference interval used in the laboratory is 0.4-4.0 mIU/L. Serum FT
4
 
was measured with a luminescence enzyme immunoassay on a random-access assay system 
(Vitros ECI; Ortho Clinical Diagnostics). The laboratory reference interval is 8.0-22.0 pmol/L. 
The Rotterdam Study (RS) is a prospective population-based cohort study of determinants of 
chronic disabling diseases in 7983 Caucasian elderly men and women from the western part 
of the Netherlands.12 In a random selection of 1855 participants TSH measurements were done 
at baseline (October 1989 - June 1992). At the first follow-up visit (October 1993 - December 
1994), second TSH levels were measured in 1562 participants. TSH levels were measured with 
a commercial TSH assay (Lumitest; Henning, Berlin, Germany [currently Brahms]). The reference 
range of TSH was 0.4-4.3 mU/L. A total of 145 subjects were excluded because of previously 
known thyroid disease. More details about this study are described elsewhere.12 
Statistics 
We used the pair of measurements of TSH and FT
4
 to calculate the regression dilution ratio 
(RDR) with a nonparametric method, the Macmahon’s method.3-5 We first stratified the subjects 
of each study into quintiles, according to the value of the baseline measurement of TSH or FT
4
. 
The initial range (R
1
) was defined as the difference between the means of the top and bottom 
quintiles of the TSH or FT
4
 measurements. Secondly, still using the baseline quintile stratification, 
the mean values of TSH or FT
4
 of the second measurement were calculated per quintile and the 
range of the second measurements (usual range or R
2
) was calculated. 
Because of variation, the first measurement of some subjects will result in a higher value than 
the true or usual value. These subjects are more likely to be assigned to the highest quintile. 
Therefore, the upper quintile includes a disproportionately high amount of subjects whose 
baseline measurement happens to be somewhat higher than their usual value. The second 
measurement will generally result in a lower value in these subjects. As a result, the mean of 
the second measurements of subjects within the highest quintile will be lower in comparison 
to the mean of the first measurements. The opposite effect is present at the bottom quintile, 
resulting in a higher mean of the second measurements of the bottom quintile in comparison 
to the mean of the first measurements. Therefore, the range of the second measurements will 
generally be smaller than the baseline range. 
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The ratio of the two ranges, R
2
/R
1
, provides an estimate of the regression dilution ratio (RDR), 
which can be used as a measure of the extent of the variability. A measurement with a high 
variation will result in a lower second range and therefore have a low RDR. A measurement 
with no variation at all will result in an equal second range and therefore will have a high RDR 
of 1. A change of the mean of serum TSH or FT
4
 during time in the population will decrease or 
increase all second quintiles, but will not have an effect on the range of the second quintiles 
and will not affect the RDR.
The RDR can be used to adjust the association between the baseline measurements and the 
disease rate. For example, one finds a relative risk (RR) of 2.0 for myocardial infarction for the 
upper versus lower quintile of the baseline cholesterol measurements. At baseline, the mean 
cholesterol levels of the upper and lower quintiles are 6 and 2 mmol/l respectively (range 4 
mmol/L). Suppose at second survey, the mean cholesterol levels of the upper and lower quintiles 
are 5.5 and 2.5 mmol/L respectively (range 3 mmol/L), than the RDR =3/4. The true estimate 
is a relative risk of 2.0 for a 3 mmol/L difference instead of 2.0 for a 4 mmol/L difference. To 
express the relative risk for a true 4 mmol/L difference in cholesterol level one could multiply 
the regression coefficient (ln RR) by 4/3 (i.e. 1/RDR): the relative risk for a 4 mmol/L difference in 
cholesterol is 2.5 (exp(ln(2.0)/0.75), (the adjustment by using the RDR should be made on the 
natural logarithm of the relative risk instead of on the relative risk itself).
 5
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results
Table 1 and figure 1 show the mean values of the log-transformed TSH and FT
4
 values of each 
of the at baseline-defined quintiles by cohort. The RDRs of serum TSH in the NBS and RS were 
0.74 and 0.78, respectively. The RDR of serum FT
4
 in the NBS was 0.77. This means that the 
point estimate of an association in studies using one single measurement is underestimated by 
approximately 33% (1/0.75). 
The RDRs of serum TSH were similar for women and men, 0.75 and 0.74 respectively in the 
NBS and 0.80 and 0.77 in the RS. The RDRs of serum TSH in participants, excluded because of 
known thyroid disease were 0.42 in the NBS and 0.52 in the RS. 
Table 1.  
Mean TSH (log) and FT
4
 per quintile and RDR
nBS rS
Baseline survey Second survey Baseline survey Second survey 
TSH quintile 1 -0.50 -0.34 -0.56 -0.51
TSH quintile 2 0.05 0.04 0.13 -0.03
TSH quintile 3 0.31          1.59 0.24          1.18 0.47          2.04 0.28          1.59
TSH quintile 4 0.59 0.46 0.79 0.48
TSH quintile 5 1.09 0.84 1.48 1.08
RDR 1.18/1.59=0.74 1.59/2.04=0.78
FT
4
 quintile 1 10.4 11.4 - -
FT
4
 quintile 2 12.0 12.6 - -
FT
4
 quintile 3 12.9          5.7 13.5          4.4 - -
FT
4
 quintile 4 13.9 14.3 - -
FT
4
 quintile 5 16.1 15.8 - -
RDR 4.4/5.7=0.77
RDR: regression dilution ratio (range second survey divided by range baseline survey). 
NBS: Nijmegen Biomedical Study. RS: Rotterdam Study.
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Figure 1.  
Mean values of TSH (log-transformed) per quintile (based on the first measurements) at baseline and at second survey. 
RDR is range second survey divided by range baseline survey.
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Discussion
Due to regression dilution bias, the association between thyroid function and disease rates or 
mortality rates in studies, based on one single measurement, is underestimated.3-6 Due to an 
increase of variation over time, a longer period between baseline measurements and outcome 
assessment results in a higher degree of underestimation. The difference between short-term 
and long-term variation may be due to changes beyond chance variation, like change of age, 
weight, diet, smoking, medication and co-morbidity. In several long-term studies regarding the 
relationship between cardiovascular risk factors and cardiovascular disease, the underestimation 
is corrected for this bias using the RDR.3, 13, 14 For example, the RDR of homocysteine was 
estimated 0.83 after 2 years and 0.71 after 6 years. The RDR after 10 years for cholesterol and 
blood pressure were estimated 0.65 and 0.52, respectively. (4;14) For the relationship between 
thyroid function and disease rates, most studies are based on a single measurement and do not 
address the point of underreporting the true risk due to intraindividual variability. 
We estimated the degree of this underestimation by assessing the RDR of TSH and FT
4
 in 2 large 
population-based studies in the Netherlands. There are several methods to estimate the RDR. 
We used the Macmahon’s method. We choose for this method because of the simplicity and 
because of the relative short follow-up time. 
We found that the RDRs for TSH were 0.74 and 0.78 in the NBS and the RS, respectively. 
This means that the estimated association in studies using one single measurement, is 
underestimated by approximately 33% (1/0.75). We can directly apply this approach on data 
of the RS concerning the relationship between TSH levels and atrial fibrillation. Heeringa et 
al. found an association between TSH level within the normal range and the risk of atrial 
fibrillation in the RS.15 The published hazard ratio (HR) was 1.94, lowest versus highest quartile, 
based on one single measurement of TSH. The corrected HR for the baseline TSH levels of 
the lowest versus highest quartiles is actually 2.33 (this HR of 2.33 could be calculated as: 
exp(ln(1.94)/0.78)). One should be aware that this RS example is an simplified conceptual 
example, for an adjustment of estimates of multivariate models and for the calculation of 
confidence intervals we refer to the statistical literature. (16) In the NBS and the RS, the interval 
between the measurements was relatively short. The underestimation of the point estimates in 
studies using one single measurement is even more distinct in studies with a longer follow-up 
time.3 
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There are some limitations of the RDR corrections. The assumption is made that disease 
risk depends on a single underlying long-term exposure, instead of a time-dependent true 
underlying exposure. In studies with a follow-up of more than a few years, a ‘life-course’ 
approach is more appropriate. If the risk of disease is also dependent on past levels of TSH/
FT
4
, a ‘non-life-course method’ can lead to overcorrection of association.16, 17 Another pitfall 
of correction with the RDR is the fact, that the observed TSH-disease association may reflect 
unmeasured confounding rather than a causal association. RDR corrections amplify such an 
association.  
In conclusion, we found that associations between TSH/FT
4
 and disease rates, estimated in 
studies using one single measurement, are underestimated by approximately one-third due to 
regression dilution bias. Clinicians and researchers should be aware that studies based on a 
single measurement of TSH or FT
4
 do underestimate the true risk. 
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Abstract
objective  
Several cross-sectional studies in populations with iodine deficiency showed that TSH-levels are 
negatively associated with age, while in populations with high iodine intake TSH is positively 
associated with age. The question is whether such an age-thyroid function relation is an 
ongoing process apparent also in longitudinal studies and whether it reflects an actual iodine 
deficiency or an iodine insufficiency in the past. 
Methods  
In an area with a borderline iodine status in the past we studied 980 participants of the 
Nijmegen Biomedical Study. We measured serum TSH, FT
4
, total T
3
, peroxidase antibodies and 
the urine iodine and creatinine concentration 4 years after our initial survey of thyroid function 
in which we reported a negative association between TSH and age. 
results  
Within 4 years TSH decreased with 5.4% (95% CI 2,5%-8,3%) and FT
4
 increased with 3.7% 
(95% CI 2.9%-4.6%). Median urinary iodine concentration was 130 µg/L. Estimated 24 hours 
iodine excretion was not associated with TSH, T
3
, change of TSH or FT
4
 over time or with the 
presence of TPOAb. Only FT
4
 appeared to be somewhat higher at lower urine iodine levels: a 
1.01% (95% CI 0.17-1.84) higher FT
4
 for each lower iodine quintile. 
Conclusions  
In this longitudinal study, we found an ongoing decrease of TSH and increase of FT
4
 in a 
previously iodine insufficient population, despite the adequate iodine status at present. This 
suggests that low iodine intake at young age leads to thyroid autonomy (i.e. a tendency to 
hyperthyroidism) that persists despite normal iodine intake later in life.
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Introduction
Iodine is an essential micronutrient and an important component of thyroid hormones. 
Iodine deficiency can cause thyroid dysfunction, goiter and cretinism.1 Monitoring the iodine 
status and maintaining an optimal iodine intake is very important to prevent brain damage in 
newborns and thyroid function disorders at all ages. Iodine deficiency remains a global public 
health problem.2 To assess the iodine status of a population, the median iodine concentration 
of series of single urine samples is the most widely used measurement.1, 3 In large population 
studies, there is a leveling out of the day-to-day variation and the median value of the urinary 
iodine concentration in samples can be used to assess whether a population is iodine sufficient.4 
According to the World Health Organization (WHO) criteria, a population has an optimal iodine 
intake if its median urine iodine concentration is between 100 and 199 µg/L and no more than 
20% of the population has an urinary iodine concentration of 50 µg/L or less.1, 3 
In the past, mild iodine deficiency was present in the eastern and southern part of the 
Netherlands.5-7 Iodine supplements were instituted as of 1935. Since then, several additional 
measures, like the compulsory use of iodized salt in bakeries, instituted in 1963, were taken 
to achieve a daily intake of iodine within the optimal range as recommended by the WHO.3 
Currently, the iodine status of the Netherlands is considered to be adequate, based on studies 
regarding the iodine intake and urinary excretion in several regions in the Netherlands.2, 8-12 Due 
to decrease of salt consumption and reduced bread consumption, regular monitoring of the 
iodine status in the population is necessary to verify the maintenance of the adequate iodine 
status.13
Previous cross sectional population studies have shown that in populations with a history of 
mild or moderate iodine deficiency, the average serum level of thyroid stimulating hormone 
(TSH) is negatively associated with age and free T
4
 (FT
4
) is positively associated with age, which 
is probably due to the gradual development of autonomous function of the thyroid gland.14-16 
By contrast, in populations with high iodine intake, TSH is positively associated with age.17 In 
subjects of the Nijmegen Biomedical Study (NBS), a large population-based survey performed 
in Nijmegen, a municipality in the eastern part of the Netherlands, TSH is negatively associated 
with age and FT
4
 is positively associated with age.14 These associations were found in cross-
sectional surveys. The question is whether such an age-thyroid function relation is apparent also 
in longitudinal analyses and, if so, whether it reflects an actual iodine deficiency.
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Materials and Methods
Subjects 
The subjects of this study are a subset of the participants of the Nijmegen Biomedical Study 
(NBS), a large population-based survey performed in Nijmegen, a town in the eastern part of 
the Netherlands. Details of this study have been described previously.14 Approval to conduct the 
study was obtained from the Institutional Review Board of the Radboud University Nijmegen 
Medical Centre (RUNMC). A total of 2253 respondents, aged 50 to 72 years, were invited 
to participate in a study of non-invasive measurements of atherosclerosis (NBS-NIMA) of 
whom 1517 gave their informed consent. In 1052 participants of this subgroup, the iodine 
concentration was measured in fasting morning urine samples in 2006. Serum TSH and FT
4
 
were measured twice with an interval of 4 years (2002 and 2006). The mean interval between 
the measurements was 4.1 years (range 2.8-5.4 years). Triiodothyronine (T
3
) and antibodies 
against thyroid peroxidase (TPOAb) were measured in 2006. We excluded subjects with 
previously known thyroid disease, a medical history of thyroid surgery or iodine treatment, the 
use of thyromimetic and/or thyrostatic drugs and the use of medication interfering with thyroid 
function or iodine status such as amiodarone, kelp, oral corticosteroids, dopamine agonists and 
lithium. A total of 72 participants were excluded, so in total 980 participants were included in 
the current analysis. 
Laboratory methods 
Serum TSH and T
3
 were measured by an immunoluminometric assay on a random-access 
analyzer (Architect; Abbott Laboratories, Abbott Park IL 60064, USA). The reference interval 
for serum TSH used in our laboratory is 0.4-4.0 mIU/L. Serum FT
4
 was measured with a 
luminescence enzyme immunoassay on a random-access assay system (Vitros ECI; Ortho 
Clinical Diagnostics, Rochester, NY, USA). Our laboratory reference interval is 8.0-22.0 pmol/L. 
TPOAbs were measured with a fluorescence immunoenzymometric assay for the quantitative 
measurement of the IgG class of anti-thyroperoxidase antibodies (AxSYM, Abbott Laboratories, 
Abbott Park IL 60064, USA). The reference interval was defined as <12 kIU/L (data provided 
by manufacturer). More details about these measurements are described elsewhere.14 In order 
to control a possible drift in assays between the 2 study periods, we repeated TSH and FT
4
 
measurements of pooled plasma with TSH and FT
4
 in the lower, middle and higher range. For 
TSH, the control samples showed a drift of -2.2, -6.0, and -9.6% for the lower, middle and 
higher range, respectively. For FT
4
, the control samples showed a drift of -9.7, -5.7 and -1.8% 
for the lower, middle and higher range, respectively. We suspected that a bias was introduced 
during analysis of the control samples, perhaps by sample instability in the freezer or some 
other unknown factor. Therefore, we choose to use the original results of the assays.
CHAPTer 6 | Thyroid function and iodine intake
113
To assess the iodine status of our population, we calculated the median urinary iodine 
concentration, obtained from single urinary samples, as recommended by the WHO.1, 3 For 
the individual subjects, we used the estimated 24-hour iodine excretion, adjusted for age and 
gender, as an indicator for the iodine status. The estimated 24-hour urinary iodine excretion 
was calculated as follows: iodine (µg/L)/creatinine (g/L) x expected 24-hour creatinine (g/day).18-
20 A large Belgian population study provides data on the expected creatinine excretion per 
individual, taking age and sex into account.21 The urine iodine concentration was measured 
with the Ammonium Persulfate Destruction Microplate (APDM) method, using a Peltier Thermal 
Cycler (PTC-200) for the heating and cooling process.22 The urinary creatinine concentration 
was measured with an enzymatic assay (Roche, Basel, Switzerland) on the Aeroset chemistry 
analyser (Abbott Laboratories, Illinois, USA).
Statistical analysis 
Because of a skewed distribution of the urinary iodine concentration, we used quintiles of the 
estimated 24-hour urinary iodine excretion for stratification. We displayed geometric means of 
FT
4
 and TSH with its 95% confidence intervals. We expressed change over time of TSH and FT
4
 
as a percentage of change. We performed logarithmic transformation of and TSH for regression 
analysis. Linear regression analysis was performed in order to investigate the relationship 
between thyroid function and iodine excretion. Each model included the estimated 24-hour 
urine iodine excretion as the independent variable and a thyroid function parameter (either FT
4
, 
T
3
, TSH or change of TSH or FT
4
 over time) as the dependent variable. To control for possible 
confounding we added age, gender, BMI and current smoking status to the models. We 
analysed the data with STATA version 11.0 (StataCorp, Texas). 
 6
Thyroid function and iodine intake | CHAPTer 6
114
results
The characteristics of the population are shown in table 1. The median urinary iodine 
concentration was 130 µg/L. The median urinary iodine concentration was higher in men in 
comparison to women, 156 µg/L versus 104 µg/L respectively. The urinary iodine concentration 
was less than 50 µg/L in 15% of the participants. The urinary iodine concentration was less 
than 50 µg/L in 9% of the men and in 20% of the women. Due to a higher urinary creatinine 
concentration, men had a lower urinary iodine/creatinine ratio in comparison to women (135 
µg/g versus 171 µg/g, respectively). However, the median estimated 24-hour urinary iodine 
excretion, taking age and gender into account, was higher in men in comparison to women 
(208 µg/day versus 186 µg/day, respectively). 
Table 1.  
Population characteristics.
Total Men Women
Number 980 492 488
Mean age (range), years 61 (50 to 72) 62 (50 to 72) 61 (50 to 71)
Serum TSH in 2002 (mIU/L)a  1.35 (1.30 to 1.41) 1.35 (1.28 to 1.42) 1.35 (1.27 to 1.43)
Serum TSH in 2006 (mIU/L)a 1.29 (1.24 to 1.34) 1.30 (1.24 to 1.36) 1.28 (1.20 to 1.36)
Change of TSH over timeb -5.4% (-8.3 to -2.5%) -5.5% (-8.6 to -2.4%) -5.3% (-10.0 to 0.3%)
Serum FT
4
 in 2002 (pmol/L)a 13.0 (12.9 to 13.1) 13.0 (12.8 to 13.2) 12.9 (12.8 to 13.1)
Serum FT
4
 in 2006 (pmol/L)a 13.5 (13.3 to 13.6) 13.4 (13.2 to 13.6) 13.5 (13.3 to 13.8)
Change of FT
4
 over timeb 3.7% (2.9 to 4.6%) 2.9% (1.7 to 4.2%) 4.5% (3.3 to 5.8%)
Serum T
3
 (nmol/L)a 1.61 (1.59 to 1.62) 1.61 (1.59 to 1.63) 1.60 (1.58 to 1.62)
Presence of TPOAb (%)c 115 (11.9%) 27 (5.6%) 88 (18.2%)
Urinary Iodine conc (µg/L)d 130 (70 to 211) 156 (91 to 238) 104 (55 to 176)
Urinary Creatinine conc (g/L)d 0.89 (0.4 to 1.5) 1.2 (0.7 to 1.8) 0.6 (0.3 to 1.0)
Iodine/Creatinine ratio (µg/g)d 154 (109 to 212) 135 (101 to 186) 171 (120 to 241)
Estimated 24-hour urinary iodine  
excretion (µg/day)d
199 (145 to 274) 208 (151 to 287) 186 (134 to 262)
TSH, thyroid stimulating hormone; FT
4
, free T
4
; TPOAb, antibodies against thyroid peroxidise; Conc, concentration.
a Geometric means (95% CI)
b Percentage change of TSH and FT
4
 from 2002 until 2006, geometric means (95% CI)
c TPOAb missing in 14 subjects
d Median (interquartile range)
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During the follow up period of 4 years, the average TSH decreased with 5.4% (95% CI 2.5% to 
8.3%, p-value <0.001) and FT
4
 increased with 3.7% (95% CI 2.9% to 4.6%, p value <0.001) 
(Table 1).
A lower quintile of estimated 24-hour iodine excretion was associated with a 1.01% higher 
FT
4
 (95% CI 0.17 to 1.84, p for trend along quintiles 0.02, adjusted for age, gender, BMI and 
current smoking status). There was no significant association between the TSH level and the 
estimated 24-hour iodine excretion after adjustment for age, gender, BMI and current smoking 
status: a lower quintile of urinary iodine excretion resulted in a 0.17% higher serum TSH (95% 
CI -3.0 to 3.2, p for trend along quintiles 0.92). There was no association between T
3
 and the 
estimated 24-hour iodine excretion.
There was no association between iodine excretion and the percentage of decrease of TSH 
or increase of FT
4
: a higher quintile of the estimated 24-hour iodine excretion resulted in a 
1.4% stronger decrease of TSH over time (95% CI -1.0 to 3.6, p for trend along quintiles 0.25 
after adjustment for age, gender, BMI and current smoking status) and a lower quintile of 
the estimated 24-hour iodine excretion resulted in a 0.4% stronger increase of FT
4
 over time 
(95% CI -0.3 to 1.0, p for trend along quintiles 0.26 after adjustment for age, gender, BMI and 
current smoking status).
There was no relationship between the presence of TPOAb and estimated 24-hour urinary 
iodine excretion (data not shown). After exclusion of subjects with TPOAb, the analyses of 
TSH, FT
4
 and T
3
 gave similar results (data not shown). Analyses with TSH or FT
4
 and iodine as 
(logtransformed) continuous variables gave similar results (data not shown).
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Discussion
Despite the fact that our population has an optimal iodine intake at this moment, we found an 
ongoing decrease of TSH and increase of FT
4
 over time. The decrease of TSH and the increase 
of FT
4
 in the 4 years follow up period was even larger than we expected, based on the cross-
sectional data in 2002. Iodine excretion was in the recommended range and was not associated 
with a change in TSH or FT
4
. One might speculate that the decrease of TSH and increase of FT
4
 
with age in our population is caused by mild iodine deficiency in the past and not by iodine 
deficiency in the present. Iodine deficiency in the past may have led to autonomous thyroid 
function, which at present causes an ongoing increase of FT
4
 and decrease of TSH over time.   
The mechanism by which mild iodine insufficiency leads to thyroid autonomy is only partially 
understood. In case of mild iodine deficiency, low iodine intake might lead to a reduced T
4
 and 
T
3
 production. In order to prevent this, several TSH-independent autoregulatory mechanisms 
are triggered, such as an increase in vascularity, an increase in iodine uptake and increased T
3 
production and secretion, at the expense of T
4
.23 If these mechanisms fail, TSH levels will rise as 
a response to a lower thyroid hormone production. TSH stimulates follicular cell replication and 
due to the higher replication rate, the chance of activating mutations in the TSH-receptor gene 
leading to TSH-independent growth and function, is increased.24 This and other mechanisms 
lead to autonomous function of the thyroid and, especially when iodine intake is supplemented, 
to hyperthyroidism.
We found that a lower estimated 24-hour iodine excretion was associated with a somewhat 
higher serum FT
4
. However, we found no relationship between TSH and the estimated 24-
hour urinary iodine excretion. Previous studies reported conflicting results on the relationship 
between urinary iodine excretion and thyroid function. Haddow et al. found no relationship 
between urine iodine concentration and thyroid function and only a weak positive association 
between the urinary iodine/creatinine ratio and TSH.25 Their study was performed in an iodine 
sufficient population, where TSH increases with age.17 Hwang et al. found that the urinary 
iodine/creatinine ratio had a negative correlation with FT
4
 and showed a positive trend with TSH 
in a Korean population, with a high iodine intake.26 In this Korean study, creatinine adjustment 
of urine iodine measurements was done without taking gender and age into account.
We used the estimated 24-hour iodine excretion, adjusted for age and gender, as an indicator 
for the iodine status of individuals. Assessing the iodine status of individuals is difficult. The 
within-day and day-to-day variation in urinary iodine excretion is large.27 Therefore, repeated 
24-hour urine samples are considered to be the best measure.28 However, 24-hour collections 
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are not very practical to perform when large numbers of persons have to be investigated. To 
minimize the variation in urinary iodine concentration caused by a variable urinary volume, 
the iodine / creatinine ratio (I/C ratio) has also been used to assess the iodine status. However, 
creatinine excretion varies with sex, age, cultural and genetic background. That is the reason 
why adjustment for age and sex is recommended.18, 19, 27, 28 This can be done by estimating the 
24-hour iodine excretion, using the expected 24-hour creatinine. A large Belgian population 
study provides data on the expected creatinine excretion per individual, taking age and sex into 
account.21
Our study has a few limitations. Our study is a subset of a large epidemiological study, the 
NBS-NIMA study. Because of the nature of the NBS-NIMA survey, urinary iodine measurements 
were only performed in subjects aged between 50 and 72 years old. Second, as already 
mentioned, assessing the iodine status of an individual is difficult due to variation of iodine 
intake and excretion. Due to the variation in iodine excretion, the relationship between iodine 
excretion and thyroid function parameters might be underestimated as a result of regression 
dilution bias.29-31 Third, the fact that sera from 2002 and 2006 were assayed several years apart 
introduced a potential bias. Although this potential bias by variation in assay is inescapable in 
every large population study using biochemical analyses at different moments, this problem is 
not always recognized and addressed. Finally, although previous population studies showed a 
iodine insufficiency in the past in this part of the Netherlands, we have no historical data on 
iodine excretion of this cohort to support our hypothesis that the current changes in thyroid 
function are due to iodine insufficiency in the past.5-7 
In conclusion, in this longitudinal study, we found an ongoing decrease of TSH and increase of 
FT
4
 in a previously iodine insufficient population, despite the adequate iodine status at present. 
This suggests that low iodine intake at young age leads to thyroid autonomy (and a tendency to 
hyperthyroidism) that persists despite normal iodine intake later in life. 
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Abstract
Background  
In populations with mild iodine deficiency, serum level of thyrotropin (TSH) is negatively and 
serum free T
4
 (FT
4
) is positively associated with age. An ongoing decrease of TSH and increase 
of FT
4
 can be found after supplementation of iodine. The aim of this study was to investigate 
whether there are current differences in the relation between thyroid function and age in 
relation to differences in iodine intake in the past.
Methods  
Eight medical laboratories in several regions of the Netherlands, which are all iodine sufficient 
at present, but with a difference in iodine status in the past, provided the results of all TSH and 
FT
4
 measurements performed from 2006 until 2011, resulting in 330,802 TSH and 103,940 FT
4
 
measurements.  
results  
The negative association between TSH and age in elderly is only present in areas with a 
historically iodine deficiency (RC -0.008, 95% CI -0.009;-0.007). In the historical iodine 
sufficient population, TSH shows no obvious increase or decrease with age. In both the 
historically iodine sufficient and deficient populations, FT
4
 levels were positively associated with 
age in elderly (RC 0.009, 95% CI 0.008;0.010 and RC 0.008, 95% CI 0.007;0.010 respectively). 
Conclusions  
There are differences in relation between thyroid function and age between populations with 
differences in iodine intake in the past, despite an adequate iodine status at present. This raises 
the question whether the present but also historical iodine status of a population should be 
taken into account when establishing the reference limits of TSH and FT
4.
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Introduction
Iodine is an important component of thyroid hormones. Severe iodine deficiency can cause 
primary hypothyroidism and cretinism. In case of mild iodine deficiency, several autoregulatory 
mechanisms within the thyroid are triggered to prevent hypothyroidism.1 When these 
mechanisms fail, there is an increase of thyrotropin (TSH) secretion through hypothalamic/
pituitary feedback in order to maintain euthyroidism. The compensatory mechanisms 
within the thyroid and the continuous TSH stimulation eventually may lead to growth and 
autonomous function of the thyroid gland and, especially when iodine is supplemented later, to 
hyperthyroidism.
Some large population based studies, such as the NHANES III study, reported that serum TSH 
level is positively associated with age in populations with adequate or high iodine intake.2-6 
The fact that elderly have on average higher TSH values in these iodine sufficient populations is 
one of the reasons why it has been suggested to increase the upper reference limit of normal 
serum TSH in elderly.7, 8 However, other cross-sectional population studies have shown that 
in populations with mild or moderate iodine deficiency, the average serum level of TSH is 
negatively and that of free T
4
 (FT
4
) positively associated with age, probably due to autonomous 
function of the thyroid gland.9-12 The suggestion of increasing the upper limit of the reference 
range of serum TSH in elderly seems therefore not appropriate for these populations. 
Knudsen et al. showed a different association between serum TSH level and age in two areas 
in Denmark with slightly different iodine status.10 In Aalborg, an area with moderate iodine 
insufficiency, there was a decline in serum TSH levels with age, whereas in Copenhagen, an 
area with only a very mild iodine insufficiency, this decline was not present. So, even within a 
relatively small geographic area, differences of iodine intake seem to influence the relationship 
between thyroid function and age. 
In the past, mild iodine deficiency was present in the eastern and southern part of the 
Netherlands.13-15 After the introduction of the water supply system (around 1900), the 
prevalence of goiter increased in the eastern and southern part of the country. The ground 
water that was used for the water supply system contained less iodine than the previously used 
more superficial ground water and contained less iodine in the eastern and southern part of 
the Netherlands than in other parts of the Netherlands.15 Iodine supplementation was instituted 
as of 1935. Since then, several additional measures, like the compulsory use of iodized salt in 
bakeries, instituted in 1963, were taken to achieve a daily intake of iodine within the optimal 
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range as recommended by the World Health Organization (WHO).16 Despite these efforts at 
increasing iodine intake, in 1981 the iodine status was still insufficient in the eastern part 
of the Netherlands and goiter was more prevalent in comparison to the western part of the 
Netherlands.15, 17 Therefore, in 1982, the amount of iodized salt in bakeries was increased. 
Currently, the iodine status of the Netherlands is considered to be adequate, based on studies 
regarding iodine intake and urinary excretion in several regions in the Netherlands.18-24 
In subjects of the Nijmegen Biomedical Study (NBS), a large population-based survey in the 
eastern part of the Netherlands, serum TSH level is negatively associated with age and FT
4
 level 
is positively associated with age.12 Despite the adequate iodine status of this population at this 
moment, a currently ongoing decrease of TSH levels and increase of FT
4
 levels in subjects 50-72 
years old was found in a longitudinal study.25 The decrease of TSH and increase of FT
4
 with age 
in this population is probably caused by the mild iodine deficiency in the past. Iodine deficiency 
in the past may have led to autonomous thyroid function, which at present causes an ongoing 
increase of FT
4
 levels and decrease of TSH levels over time.
These studies suggest therefore that both the current and the past iodine intake can influence 
the relationship between thyroid function and age. Because iodine insufficiency in the past 
seems to cause an ongoing increase of FT
4
 and decrease of TSH even after attaining an 
adequate iodine status, we hypothesized that there might also be differences in the relationship 
between thyroid function and age in populations that had a different iodine intake in the 
past. Therefore, the aim of this study was to investigate the relation between thyroid function 
and age in populations from several geographic regions in the Netherlands which are iodine 
sufficient at present but had a different iodine intake in the past. 
Materials and Methods
To sample several regions with different iodine intake in the past we used routinely achieved 
TSH and FT
4
 levels from laboratories that perform these measurements ordered by general 
practitioners for screening purposes. Because thyroid hormone assays are ordered with high 
frequency we hypothesized that the results are representative for the regional population. 
Eight large medical laboratories were invited to participate. The laboratories were chosen 
for their geographic localization in the Netherlands, namely either in the historically iodine 
deficient southern/eastern part of the Netherlands or in the historically iodine sufficient 
western part of the Netherlands.15 The participating laboratories were situated in the cities 
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Nijmegen, ‘s-Hertogenbosch, Doetinchem, Helmond, Breda, Haarlem, Amsterdam and Leiden. 
They each provided the results of all TSH and FT
4
 measurements performed at the respective 
laboratories from 2006 until 2011 (the measurements from Leiden were performed in 2013 
only, the measurements from Amsterdam were performed from 2006 until 2013). For each 
person in whom TSH or FT
4
 level was measured, data on age and gender were provided. 
All measurements of TSH and FT
4
 were performed on request of a general practitioner in 
outpatients. Serum TSH (3rd generation assay) and FT
4
 levels were measured by random access 
analyzers (ECLIA Modular E170, Roche; LEIMA Cobas 6000, Roche; ECLIA Dimension Vista, 
Siemens; LEIMA Immulite 2000, Siemens; CLIA DxI800, Beckman Coulter). Details of the 
participating laboratories and the laboratory methods are shown in Supplementary Table 1.         
To ensure that we included only the treatment naïve patients we applied the following strategy. 
We assumed that when thyroid hormone levels of a patient without previously known thyroid 
disease are measured, this is probably because of symptoms like fatigue or weight gain etc. 
Most of the time, the general practitioner will also order some other blood analyses in order 
to screen for common diseases in such symptomatic patients. Some of the participating 
laboratories offer a package of several blood analyses to general practitioners to screen for 
some common causes of fatigue in patients. These packages for example include glucose level, 
erythrocyte sedimentation rate, hemoglobin level and TSH level. When such package was 
available at a laboratory, only these TSH measurements were included. If such package was 
not available, only TSH measurements were included if glucose and hemoglobin level were 
measured at the same time. In one laboratory (Helmond), glucose levels were not available, but 
hemoglobin levels were required for inclusion. We assumed that most patients using thyroid 
medication get their thyroid hormones level monitored periodically by measuring TSH and/or FT4 
levels only. Therefore, we excluded all subjects in whom only a serum TSH and/or a FT
4
 level was 
measured.  
Historical data of iodine status in the regions of the participating laboratories are shown in 
Table 1. In Haarlem, Leiden and Amsterdam, three cities situated in the western part of the 
Netherlands, low goiter prevalence has been reported in the past (1951) whereas a high goiter 
prevalence has been reported in the cities in the eastern/southern part of the Netherlands.26 
Iodine intake was higher in Leiden in the late seventies in comparison to some cities (including 
Helmond and Nijmegen) in the eastern/southern part of the Netherlands.15 In the early 
eighties, iodine intake was still insufficient in women (in Doetinchem, Helmond but also in 
Leiden).13 For the past 20 years, a sufficient iodine intake has been reported in all regions of the 
Netherlands.18-24
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Table 1.  
Overview of historical data on iodine status of participating regions.
Geographic region in The 
netherlands
Historical data on iodine status
nijmegen Eastern part 1951 goiter prevalence 40-60%26
1977 urinary iodine excretion 80 µg/day,  
goiter prevalence 47%15
2006 median urinary iodine concentration 130 µg/l25
’s-Hertogenbosch Southern part 1951 goiter prevalence 20-30%26
Helmond Eastern-southern part 1951 goiter prevalence 40-60%26
1987 urinary iodine excretion ♀111-♂135 µg/day,  
goiter prevalence 31-39%13
Doetinchem Eastern part 1951 goiter prevalence >60%26
1977 urinary iodine excretion ♀69-♂118 µg/day,  
goiter prevalence 20-50%15
1987 urinary iodine excretion ♀122-♂157 µg/day,  
goiter prevalence 20-35%13
1995 median urinary iodine concentration 151-166 µg/l,  
goiter prevalence 0.8%20
2006 urinary iodine excretion 236 µg/day24
2010 urinary iodine excretion 165 µg/day24
Breda Southern part 1951 goiter prevalence 40-60%26
Haarlem Western part 1951 goiter prevalence 0-20%26
1995 median urinary iodine concentration 142-168 µg/l,  
goiter prevalence 2.6%20
Amsterdam Western part 1951 goiter prevalence 20-30%26
1995 median urinary iodine concentration 142-168 µg/l,  
goiter prevalence 2.6%20
Leiden Western part 1951 goiter prevalence 20-30%26
1977 urinary iodine excretion ♀123-♂126 µg/day, goiter  
prevalence 8-10%15
1987 urinary iodine excretion ♀114-♂153 µg/day, goiter  
prevalence 7-32%13
CHAPTer 7 | Thyroid function versus age
127
Statistical analysis  
We standardized the TSH and FT
4
 values in order to show the results of different laboratories 
combined, using z scores (the number of standard deviations that a value differs from the 
mean). Because of a skewed distribution of TSH, TSH measurements were (natural) log 
transformed and we displayed geometric means of TSH with its 95% confidence intervals when 
presenting the results per laboratory separately (supplementary data). Linear regression analysis 
was used in order to describe the association between thyroid hormones (z scores, TSH after 
logtransformation) and age. Because of a non-linear relationship between thyroid hormones 
and age, as shown by figure 1, the population was divided in different age categories (0-35; 35-
60; 60 years or older) and linear regression analyses was performed per age category. In order 
to compare the regression coefficients (RC), we included an interaction term in the regression 
model.
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results
In total, 894,435 TSH measurements and 448,655 FT
4
 measurements were obtained. A total 
of 330,802 TSH and 103,940 FT
4
 measurements were performed in combination with (glucose 
and) hemoglobin measurements and these results were used for analyses. The numbers of 
included TSH and FT
4 
measurements per laboratory are shown in Supplementary Table 1.
Figure 1 shows the standardized values of TSH and FT
4
 for the eastern/southern part 
(‘s-Hertogenbosch, Nijmegen, Doetinchem, Helmond and Breda) and the western part of the 
Netherlands (Amsterdam, Leiden and Haarlem). In both the eastern/southern part and the 
western part, average TSH levels are negatively associated with age during young adulthood. 
In the eastern/southern part, average TSH levels then increase gradually from approximately 35 
years until the age of 60 years. In the elderly (60 years or older), average TSH levels decrease 
with age (RC -0.008, 95% CI -0.009;-0.007, this corresponds with a decrease of 0.7% of the 
average TSH level per year). In the western part, TSH shows no obvious increase or decrease 
with age in the population of approximately 35 years and older (age 60 years or older: RC 
-0.002, 95% CI -0.003;-0.001, this corresponds with a decrease of 0.1% of the average TSH 
level per year). The effect size is only very small and when considering figure 1, we conclude 
that there is no obvious trend of decrease or increase of TSH in elderly in the western part. The 
difference in RC between the eastern/southern part and western part in elderly is 0.006, 95% 
CI 0.004-0.007, p<0.001. 
The average FT
4
 levels in the eastern/southern part show the opposite pattern of the TSH 
levels in this area: the FT
4
 levels are positively associated with age during young adulthood and 
then decrease until the age of 60 years. In subjects aged 60 years or older, FT
4
 levels further 
increase with age (RC 0.008, 95% CI 0.007-0.010, this corresponds with an increase of 0.04 
pmol/L of the average FT
4
 level per year). In the western part, FT
4
 levels show no obvious 
increase or decrease with age until the age of 60 years. In subjects, 60 years or older, FT
4
 levels 
are positively associated with age (RC 0.009, 95% CI 0.008;0.010, this corresponds with an 
increase of 0.04 pmol/L of the average FT
4
 level per year).
Supplementary Figure 1 shows the geometric means of TSH levels by age per laboratory. 
Supplementary Figure 2 shows the means of FT
4 
levels by age per laboratory. 
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Discussion
The aim of this study was to investigate whether there are differences in the relation between 
thyroid function and age between populations with differences in iodine intake in the past, 
despite an adequate iodine status at present, indicating that the TSH/FT
4
 versus age relationship 
could be used as an indicator of historical iodine status. Our results show that the negative 
association between TSH and age in elderly (60 years or older) is only present in areas with a 
history of (mild) iodine deficiency. In the areas with a historical more adequate iodine status, 
TSH levels were neither positively nor negatively associated with age. An explanation for these 
findings could be the fact that due to mild iodine deficiency in the past, several compensatory 
mechanisms within the thyroid and continuous TSH stimulation have led to growth and 
autonomous function of the thyroid. When thereafter iodine intake is supplemented, a 
tendency to hyperthyroidism may develop. Another explanation could be that iodine deficiency 
has an epigenetic effect early in life, perhaps even prenatally, which is persistent despite of 
iodine repletion.
Our results agree with those of Knudsen et al, which showed a different association between 
TSH and age in two areas in Denmark with slightly different iodine status at present.10 In our 
study, in the previously iodine deficient area, we could detect the negative association between 
TSH and age in elderly (60 years or older) only. By contrast, in younger subjects (aged 35-60 
years old), TSH was positively associated with age, causing a remarkable curve in the TSH-age 
relationship figure. The reason for this might be the fact that the younger subjects are not 
exposed to iodine deficiency in the past, due to the mandatory use of iodized salt in bakeries 
in the Netherlands since 1963 and the successive efforts of the Dutch government to achieve 
an adequate iodine status since then. Therefore, the younger subjects are less likely to have 
developed growth and autonomous function of the thyroid. We hypothesize that if one would 
examine the relationship between TSH and age in several decades in this area, one might find 
a positive association between TSH and age in all age groups 35 years or older. Probably the 
results would then be more in line with the results of the NHANES III study, a large population 
study in an iodine sufficient area, which reported a positive association between TSH and age in 
all age groups.2 
In the historical iodine deficient area, FT
4
 levels are negatively associated with age in subjects 
aged 35-60 years and positively associated with age in the young subjects aged 35 years or 
younger and in the elderly, aged 60 years or older, i.e. the exact opposite of the associations 
between TSH levels and age in this area, as one would expect. However, despite the lack of a 
positive or negative association between TSH levels and age in the historical iodine sufficient 
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area, FT
4
 levels were positively associated with age in elderly in this population. It has been 
previously hypothesized that there is a change of pituitary TSH set point in elderly and higher 
FT
4
 levels do not cause the same TSH suppression as in younger individuals.4, 5 Possible 
mechanisms for this are an altered pituitary sensitivity for thyroid hormones, a decrease in TSH 
bioactivity and/or a decreased responsiveness of the thyroid gland to TSH in elderly. The studies 
of Bremner et al. and Waring et al. showed in iodine sufficient populations an increase of TSH 
with age without decrease or even a small increase of FT
4
 levels with age in elderly.4, 5
The fact that elderly have on average higher TSH values in these two study populations and in 
several other iodine sufficient populations is one of the reasons why it has been suggested to 
increase the upper reference limit of TSH level in elderly.4, 5, 7, 8 However, the present study and 
other studies reporting a lower average TSH in elderly in current or historical iodine insufficient 
populations raise the question whether, besides age and race, the present and historical iodine 
status of a population should be taken into account when establishing the reference limits of 
TSH and FT
4
.9-12 Guan et al. compared three areas with different levels of iodine intake and 
showed that the average TSH level and the 2.5th and 97.5th percentiles were lowest in the iodine 
deficient area and highest in the population with iodine excess, even in a rigorously selected 
reference population after exclusion of subjects with thyroid disease, thyroid antibodies, thyroid 
nodules/goiter or a family history of thyroid disease.27 
In our study there was a striking negative association between TSH and age and the concordant 
positive association between FT
4
 and age in the young subjects (aged 35 years and younger). 
In particular the negative association between TSH and age was a consistent finding in all the 
laboratories. Most population-based studies include adults only, so little is known about the 
relationship between thyroid function and age in children and teenagers. The population study 
of Guan et al. shows similar results: the mean TSH level in the youngest age group (14–19 
years old) was about 20%–30% higher than those in other age groups, even after exclusion of 
subjects with thyroid disease, thyroid antibodies, thyroid nodules/goiter or a family history of 
thyroid disease.27  Further studies, preferably performed in an iodine sufficient population and 
after exclusion of subjects with thyroid disease and risk factors for thyroid disease, are needed 
to confirm these interesting findings. 
A limitation of our study is the fact that we had no data on medical history of thyroid disease 
or thyroid autoimmunity of the participating subjects. In order to address this problem, we 
included only the subjects in whom a screening package of several laboratory measurements 
was performed and assumed that these subjects were less likely to have a known thyroid 
disease. Subjects on thyroid medication more likely would have their thyroid hormones level 
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monitored periodically by measuring TSH (and/or FT
4
) levels only. The results of the laboratory of 
Nijmegen, that offered a standard package, including a glucose level, erythrocyte sedimentation 
rate, hemoglobin level and TSH, to general practitioners to screen for some common causes 
of fatigue in patients, were similar to the results of the other laboratories in the historical 
iodine deficient area. Moreover, they were also similar to the results of these laboratories 
when subjects in whom only TSH and/or FT
4
 levels were measured were not excluded (data not 
shown). Due to the very large number of measurements, the effect of the few subjects with 
thyroid disease who might have been undesirably included despite our selection of combined 
measurements of glucose, hemoglobin and TSH, is probably negligible. 
In conclusion, this study shows that there are differences in the relation between thyroid 
function and age between populations with differences in iodine intake in the past, despite an 
adequate iodine status at present. The negative association between TSH and age in elderly is 
only present in areas with a history of (mild) iodine deficiency. This raises the question whether, 
besides age and race, the present but also historical iodine status of a population should be 
taken into account when establishing the reference limits of TSH and FT
4.
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Supplementary Table 1.  
Details of the participating laboratories and the laboratory methods.
number of  
TSH  
measurements 
number of FT4  
measurements
Assay TSH and  
reference values
Assay FT4 and  
reference values
Nijmegen 3574 697 Roche Modular E170, 
sandwich ECLIA 0.27-4.2
Roche Modular E170, 
competitive ECLIA 10-23 
pmol/L
’s-Hertogenbosch 90,003 15,077 Until 2009:  
Roche Modular E170, 
sandwich ECLIA  
0.35 – 4.0 mU/l  
2009-2011:  
Siemens Dimension Vista, 
ECLIA based on LOCI  
0.35 – 4.0 mU/l
Until 2009:  
Roche Modular E170, com-
petitive ECLIA 12.0 – 22.0 
pmol/l 2009-2011:  
Siemens Dimension Vista, 
ECLIA  
based on LOCI  
10.0 – 19.0 pmol/l
Helmond 51,269 5295 Beckman Coulter,  
CLIA DxI800  
0.25-3.1 mU/L
Beckman Coulter,  
LIA DxI800  
7.8-16.0 pmol/L
Doetinchem 15,631 2820 Roche E-170 Cobas 6000, 
sandwich ECLIA  
0.4-4 mU/L
Roche E-170 Cobas 6000, 
competitive ECLIA  
10.0-24.0 pmol/L
Breda 17,597 2408 Until 2009:  
Siemens Immulite 2000, 
two side LEIMA  
2009-2011  
Roche Cobas 6000,  
two side LEIMA  
0.4-4.0 mU/L
Until 2009:  
Siemens Immulite 2000, 
competitive LEIMA  
2009-2011  
Roche Cobas 6000, com-
petitive LEIMA  
9-23 pmol/L
Haarlem 6820 4010 Roche Modular E170, 
sandwich ECLIA  
0.28-4.20 mU/L
Roche Modular E170, 
competitive ECLIA  
12.0-22.0 pmol/L
Amsterdam 137,686 69,227 Roche Modular E170, 
sandwich ECLIA  
0.28-4.20 mU/L
Roche Modular E170, 
competitive ECLIA  
12.0-22.0 pmol/L
Leiden 8222 4406 Siemens Immulite 2000, 
sandwich CLIA  
0.4-4.0 mU/L
Siemens Immulite 2000, 
competitive CLIA  
10.3-24.5 pmol/L
ECLIA= Electro Chemiluminescence Immuno Assay; LOCI= Luminescent Oxygen Channeling Immunoassay;  
CLIA= Chemiluminescence Immuno Assay; LEIMA= Luminescent Enzyme Immuno Assay 
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results of this thesis in perspective
The aim of this thesis was to investigate short and long term effects of subtle differences in 
thyroid function and iodine status in the general population. We have shown that even within 
the normal range of serum TSH and FT
4
 levels, fatigue was more severe in subjects with high-
normal thyroid function. We found no association between thyroid function within the normal 
range and presence of depression. Both a high-normal serum TSH and a high-normal serum 
FT
4
 were associated with mortality in older, not in younger subjects. We have also shown that 
in populations with a mild iodine deficiency in the past, there is an ongoing decrease of serum 
TSH over time leading to a negative association between serum TSH and age, despite an 
adequate iodine status at present. Therefore, the main conclusions of this thesis are that: 
1)  subtle differences of thyroid function within the normal range are associated with short term 
effects (symptoms) and long term effects (mortality), 
2) mild iodine deficiency in the past can affect thyroid function at present. 
As summarized in the introduction of this thesis (Chapter 1), numerous previous studies 
examined the relationship between thyroid function within the normal range and cardiovascular 
risk factors, morbidity and mortality.1-43 These studies reported discrepant results on virtually 
every clinical outcome. Some studies of this thesis also provide results that are in contrast 
with other studies. For example, although we could not find an association between thyroid 
function within the normal range and depressive symptoms in middle-aged persons (Chapter 
3), a recently published population-based cohort study did find that elderly persons with low-
normal TSH levels have more depressive symptoms.44 These discrepant results can (partially) be 
explained by the different characteristics of the study populations. Our study comprised middle-
aged subjects, whereas the population of the study of Medici et al. consisted of elderly only. As 
we have shown in this thesis, age also has a major impact on the relationship between thyroid 
function and mortality (Chapter 4). When interpreting studies investigating the relationship 
between thyroid function within the normal range and clinical outcomes, the age of the study 
population should be taken into account as several associations between thyroid function and 
clinical outcomes are only found in certain age groups (often the elderly). Also gender is an 
important factor to consider. For example, recently Leader et al. found that serum TSH levels 
within the lower normal range are associated with an increased risk of hip fractures in euthyroid 
elderly women, but not in men.45 
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Besides age and gender, the present or historical iodine status of the study population could 
be an important factor to consider when interpreting studies investigating the relationship 
between thyroid function within the normal range and clinical outcomes. As we have shown in 
Chapter 6 and 7, a mild iodine deficiency in the past can affect thyroid function at present. One 
could hypothesize that the association between thyroid function within the normal range and 
clinical outcomes differs between two populations with a different iodine status. For example, 
the association between a low-normal serum TSH level and atrial fibrillation that was found in a 
population, consisting of elderly living in a historically iodine sufficient area26 might be absent in 
a population with a mild iodine deficiency at present or in the past, in which the average serum 
TSH decreases with age.
In conclusion, the fact that the numerous studies investigating the relationship between thyroid 
function within the normal range and clinical outcomes provide discrepant results can (partially) 
be explained by different characteristics of the study populations. 
Perspective on the ‘optimal’ TSH level
Thyroid function is generally considered as having a U-shaped relationship with adverse clinical 
outcomes at hyperthyroid or hypothyroid extremes. When considering the studies in this thesis 
and the previous studies regarding associations between thyroid function within the normal 
range and medical conditions, it seems that for individual symptoms/conditions there are no 
U-shaped associations within the normal range. Fatigue, depressive symptoms, atrial fibrillation, 
osteoporosis and dementia are associated with high-normal thyroid function. By contrast, 
less favorable lipid concentrations, insulin resistance, adiposity, high blood pressure, chronic 
kidney disease and myocardial infarction are associated with low-normal thyroid function.1-43, 
46 We conclude that there is no single serum TSH level within the reference range that is 
optimal. There seems to be a different optimal serum TSH level for different medical conditions. 
Moreover, this optimal serum TSH level may differ between populations with different patient 
characteristics like age, gender and iodine status. 
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Perspective on reference values of serum TSH
For some time, the reference values of serum TSH have been debated. Especially the upper limit 
of the reference range has been questioned. As noted in the introduction of this thesis (Chapter 
1), reasons to question the present reference range of TSH are the high proportion of people 
whose serum TSH is less than 2.5 mIU/L, the higher prevalence of thyroid autoantibodies in 
people with serum TSH higher than 2.5 mIU/L and the observation that people with serum TSH 
between 2.5 and 4.5 mIU/L have an increased risk of progression to overt hypothyroidism.47, 
48 However, since about 20% of the subjects without known thyroid disease, without thyroid 
autoantibodies and with normal thyroid ultrasound has a TSH level between 2.5 mIU/L and 4.5 
mIU/L and no firm evidence is available that lowering the upper limit of normal will provide any 
short- or long-term benefit for subjects, the upper limit of the reference range of TSH remained 
unchanged.49-51
Currently, the reference range of TSH values is based on the 2.5th and 97.5th percentile of the 
population. Another, more logical, approach for assessing the reference range of serum TSH 
might be to base the reference limits on clinical outcomes. That is one of the reasons why 
studies investigating the relationship between thyroid function within the normal range and 
clinical outcomes are of major interest. The results of this thesis do not support the suggestion 
of lowering the upper limit of the reference range of serum TSH. Subjects with a serum TSH 
level in the upper range of normal did not report more symptoms like fatigue or depressive 
symptoms (Chapter 2 and 3). On the contrary, subjects with a low-normal TSH experienced 
more fatigue. A high-normal serum TSH value was not associated with mortality in the general 
population (Chapter 4), with the exception of the very elderly. As described above, previous 
studies showed that there are several harmful clinical outcomes associated with a low-normal 
serum TSH whereas several other negative outcomes are associated with a high-normal serum 
TSH value.1-43, 46 Given these discrepant results, we think that lowering the limit of serum TSH 
level based on clinical outcomes is not justified.
In contrast with the suggestion of lowering the upper limit of the reference range of serum TSH 
in the general population, it has been suggested to increase the TSH upper reference limit in 
the elderly. Reason for this would be the fact that in several population-based studies, serum 
TSH is positively associated with age.52-58 These studies were performed in populations with 
normal or high iodine intake. However, as shown by the studies described in Chapter 6 and 7 
of this thesis, we found a negative relationship between TSH and age and an ongoing decrease 
of TSH over time in a population with iodine deficiency in the past. These results are in line with 
previous studies, reporting a negative relationship between serum TSH levels and age in iodine 
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deficient populations.59-62 When using the 2.5th and 97.5th percentile to assess the reference 
range of serum TSH level, the suggestion of increasing the upper limit of the reference range in 
elderly would not be appropriate for populations with a present or historical iodine deficiency. 
When basing the reference limits of elderly on clinical outcomes, the results of the Leiden 85+ 
study, that reported a protective effect of high-normal TSH values in elderly, would support 
increasing the upper limit of the reference range of TSH. Recently, Cappola et al. also reported 
that several negative clinical outcomes, including mortality, were associated with a low serum 
TSH within the normal range in elderly.46 However, the study presented in Chapter 4 of this 
thesis and two other previous studies could not confirm these findings.39, 55 By contrast, in our 
study, a high-normal TSH level was associated with mortality in the oldest elderly. Given these 
discrepant results, we think that the upper limit of the reference range of serum TSH in elderly 
for the moment should remain unchanged, pending further research that provides more clarity 
on this subject.
In contrast with the discrepant findings regarding the association between serum TSH and 
mortality in elderly, the association between a high-normal serum FT
4
 and mortality in elderly 
is a consistent finding in all studies.38, 39, 46, 55, 63 The reason why a high-normal serum FT
4
 level is 
a better predictor for mortality in elderly than a low-normal serum TSH level is not clear. These 
results might suggest that there is a change of pituitary TSH set point in elderly with higher FT
4
 
levels not causing the same TSH suppression as in younger individuals. Possible mechanisms for 
this are an altered pituitary sensitivity for thyroid hormones, a decrease in TSH bioactivity and/or 
a decreased responsiveness of the thyroid gland to TSH in elderly. 
Implications for clinical practice
This thesis comprises several population-based studies that provide the opportunity to 
investigate associations between thyroid function and health outcomes without selection bias. 
However, the question is to what extend one can apply the data of population studies to the 
individual patient. 
An important issue one should take into account when extrapolating data of population 
studies to the individual patient is the fact that each individual has his/her own set-point of 
the hypothalamic-pituitary-thyroid axis. The width of the 95% confidence interval of thyroid 
hormone levels in an individual is approximately half that of the population.64 The individual set-
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point of the hypothalamic-pituitary-thyroid axis is not only determined by environmental factors 
(such as iodine intake), but also by genetic factors.64 Therefore, an individual optimal serum TSH 
level may differ from the average optimal serum TSH level in a population. For example, in a 
patient suffering from fatigue, his or her optimal serum TSH level can still be in the lower range 
of normal due to genetic factors, despite the fact that in our population-based study a serum 
TSH level in the lower range was associated with a higher frequency and severity of fatigue 
(Chapter 2).
Another issue to keep in mind is that population-based studies are observational and mostly 
cross-sectional studies. Therefore, no causal relationship or lack of causal relationship between 
thyroid function and outcomes can be determined. Moreover, we need intervention trials 
to determine whether a possible intervention results in improvement of the negative health 
outcomes that are associated with certain serum TSH levels.
Nevertheless, a clinician can keep the results of the population studies in mind while treating 
patients. The clinician can take into account that there seems to be a different optimal serum 
TSH level for each medical condition. In clinical practice, it would fit the concept of personalized 
medicine to consider patient specific factors when deciding what would be the best treatment 
for the individual patient (i.e. what is the optimal level of serum TSH to aim for). For example, 
when treating a fatigued older woman with a medical history of osteoporosis with thyroid 
hormones, it seems reasonable to aim for a serum TSH level in the middle or upper range of 
normal, given the association between a low-normal serum TSH level and both fatigue (Chapter 
2) and an increased risk of hip fracture in older women in population-based studies.45 On the 
other hand, one could aim for a serum TSH level in the lower range in an obese middle aged 
man with hypercholesterolemia, considering the positive association between a high-normal 
serum TSH level and adiposity and lipid levels. 
A common but difficult problem in clinical practice for clinicians as well as for patients is the 
persistence of symptoms (such as fatigue) during treatment of thyroid dysfunction, despite 
optimal biochemical control (i.e. both serum TSH and FT
4
 levels within the normal range). As we 
have shown in our study described in Chapter 2 of this thesis, subjects with previously known 
thyroid disease and thyroid hormone levels within the normal range during treatment reported 
fatigue substantially more often than euthyroid subjects without known thyroid disease. It is 
important for clinicians to acknowledge the patients complaints and to explain that this is not 
rare during treatment of thyroid dysfunction. The reasons for this problem are unclear but 
subtle abnormalities in thyroid hormone levels should be considered. Substitution therapy with 
thyroid hormones is perhaps not as optimal as natural secretion of thyroid hormones, strictly 
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regulated by the hypothalamic-pituitary-thyroid axis. For instance, it is impossible to mimic 
the subtle variations in thyroid function due to biological variation (e.g. circadian or seasonal 
variation) with substitution therapy. Also, the treatment goal of the clinician is usually a serum 
TSH and FT
4
 within the normal range. However, as explained above, the individual set-point of 
the hypothalamic-pituitary-thyroid axis has a small 95% confidence interval. It is possible that a 
serum level of TSH within the normal range of the population is not within the normal range of 
the individual patient. This might cause inadequate substitution with thyroid hormones, causing 
persistent symptoms. 
Besides the possible imperfections of substitution therapy with thyroid hormones as a cause of 
persistent symptoms, the possibility that thyroid dysfunction is not the cause of the symptoms 
should be considered. In the study described in Chapter 2, we have shown that the prevalence 
of fatigue in subjects with thyroid dysfunction but without a previously known medical 
history of thyroid disease was only slightly higher than the prevalence of fatigue in euthyroid 
subjects. Because of the high prevalence of both fatigue and thyroid dysfunction in the general 
population, it is likely that many patients who seek medical care because of fatigue, happen 
to be tired and by coincidence also have thyroid dysfunction, without any causal relationship. 
Patients with fatigue are more likely to have their thyroid status tested by the general 
practitioner and (subtle) thyroid dysfunction will be found more often, despite the absence of 
a causal relationship (confounding by indication). Clinicians should be aware of this possibility. 
This issue can be discussed with the patient and, if indicated, further diagnostic investigations 
or other treatment options can be considered.
This thesis comprises two studies regarding the effect of current and historical iodine status 
on the relationship between thyroid function and age. To assess the iodine status of a 
population, measurements of urinary iodine, thyroid size, serum TSH and thyroglobulin are 
used. The median iodine concentration of series of single urine samples is the most widely used 
measurement.65, 66 Urinary iodine excretion indicates current iodine nutrition. Neonatal serum 
TSH screening also provides information on the iodine status of a population. In regions of 
iodine deficiency, the frequency of supranormal TSH concentrations in neonates is higher than 
in iodine sufficient areas and this roughly correlates with the severity of iodine deficiency.67 
Thyroid size and serum thyroglobulin concentration reflect iodine nutrition over a period of 
months or years.68, 69 In the studies described in Chapter 6 and 7 of this thesis, we show that 
the relationship between TSH and age is also an indicator of the iodine status of a population. 
In populations with a mild iodine deficiency in the past, there is an ongoing decrease of 
serum TSH over time leading to a negative association between serum TSH and age. Since the 
population of this study has been considered to be iodine sufficient for more than 30 years, we 
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can conclude that the relationship between TSH and age reflects iodine nutrition over a period 
of at least several decades. 
As part of preventive healthcare, monitoring the iodine status and maintaining an optimal 
iodine intake is very important to prevent brain damage in newborns and thyroid function 
disorders at all ages. Besides measuring urine iodine concentrations, neonatal serum TSH, 
thyroglobulin and thyroid size, one could evaluate the relationship between TSH and age in a 
population as an additional indicator of iodine deficiency at present or in the past.
recommendations for further research
As summarized previously in this thesis, there are several cross-sectional population-based 
studies investigating associations between mild thyroid dysfunction or thyroid function within 
the normal range and clinical outcomes. However, the benefits and risks of treatment of subtle 
thyroid dysfunction are still a matter of debate. Only a few randomised controlled trials have 
been performed in patients with subclinical thyroid disease (mainly in patients with subclinical 
hypothyroidism) and these trials reported discrepant results with low quality of evidence due 
to the small numbers of included patients and the small effect sizes.70-74 Therefore, large 
prospective randomized controlled intervention trials are required to assess the benefits and 
risks of treatment of subtle thyroid dysfunction. 
We concluded in this thesis that there seems to be a different optimal TSH level for each 
medical condition. This optimal serum TSH level may differ between populations with different 
patient characteristics. Therefore, it would be interesting to assess the target level of TSH during 
treatment in different pre-defined subgroups of patients (classified according to age, gender, 
medical history etc.) For example, in patients with subclinical hypothyroidism experiencing 
fatigue, one could investigate in a prospective randomized trial the effect of thyroid hormone 
replacement therapy on fatigue using different target levels of serum TSH: high-normal TSH 
target levels versus low-normal TSH target levels versus placebo. The outcome of such a study 
(i.e. the optimal TSH level) may be different from the outcome of a similar study investigating 
the effect on for example lipid levels. Also, the outcome may be different in groups with 
different patient characteristics, such as different age groups. Especially the subgroup of the 
elderly is of major interest, since some associations between thyroid function within the normal 
range and negative outcomes are different in elderly in comparison to the general population 
(Chapter 4) and serum thyroid parameters change during aging (Chapter 6 and 7). However, 
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to perform studies that investigate each symptom and medical condition separately in each 
subgroup with different patient characteristics would be a practical challenge. And even if one 
would be able to perform such studies and an optimal serum TSH would be established for a 
certain patient group, extrapolating data of these studies to the individual patient would be 
difficult since every patient has its own set-point of the hypothalamic-pituitary-thyroid axis, in 
part determined by genetic factors.
One of the striking results of this thesis is the finding that subjects with previously known thyroid 
disease but thyroid hormones levels within the normal range during treatment reported fatigue 
substantially more often in comparison to euthyroid subjects without known thyroid disease 
(Chapter 2). As already mentioned, in clinical practice this is a common and difficult problem. 
The cause of persistent symptoms after normalization of serum TSH in patients with thyroid 
disease should be clarified and further treatment options can be explored. For example, one could 
investigate the effect of changing the target of serum TSH levels, the beneficial and/or harmful 
effects of treatment with combination therapy of levothyroxine and liothyronine (T
3
) or the 
efficacy of other treatment options like cognitive behaviour therapy or rehabilitation programs.
In Chapter 6 and 7 of this thesis we have shown that in populations with a mild iodine 
deficiency in the past, there is an ongoing decrease of serum TSH over time leading to a 
negative association between serum TSH and age, despite an adequate iodine status at present. 
The negative association between TSH and age was only present in elderly (60 years or older) 
who had been exposed to iodine deficiency in the past. In younger subjects (aged 35-60 
years old), TSH was positively associated with age. We hypothesized that this difference in 
relationship is caused by the fact that the younger subjects are not exposed to iodine deficiency 
in the past. Therefore, the younger subjects are less likely to have developed growth and 
autonomous function of the thyroid. To test this hypothesis, it would be interesting to study 
the relationship between TSH and age again in the same area in several decades. Probably we 
would find a positive association between TSH and age in all age groups, in line with the results 
of the population studies performed in (historical) iodine sufficient areas. This finding would be 
an extra argument to consider this population as iodine sufficient.
As already mentioned, monitoring the iodine status and maintaining an optimal iodine intake is 
very important to prevent brain damage in newborns and thyroid function disorders at all ages. 
The new finding that mild iodine deficiency in the past causes changes in thyroid function to 
date stresses the importance of regular monitoring of the iodine status of a population in order 
to maintain an optimal iodine intake. 
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Case: a personal reflection
This thesis started with a clinical vignette presenting the case of a 74-year-old woman, living 
in an iodine deficient area, with symptoms of fatigue, weight gain and cold intolerance and a 
TSH level of 3.8 mIU/L (reference range 0.4-4.0 mIU/L) before treatment with thyroid hormone 
replacement therapy. After the initiation of thyroid hormone replacement therapy, fatigue 
persisted despite a TSH level of 2.6 mIU/L. This case raises several questions, as formulated 
in the introduction chapter (Chapter 1). When taking the results of this thesis and those of 
previous studies into account, the case can be re-evaluated as follows:
Before the start of my PhD project, I would have classified this patient without any hesitation 
or consideration as having a normal thyroid function. However, the results of this thesis yielded 
in a more nuanced and differentiated view on this topic. One argument that would favor the 
opinion that the thyroid function is abnormal in this case is that, as outlined before, each 
individual has its own setpoint of the hypothalamic-pituitary-thyroid axis and it is possible 
that this value of serum TSH of 3.8 mIU/L within the reference range is not normal for this 
individual patient, given also the presence of thyroid peroxidase antibodies. Moreover, this 
patient has presumably been exposed to iodine deficiency and the average TSH level decreases 
with age in populations with iodine deficiency. Therefore, the TSH level in the upper range of 
normal may be inadequately high for this patient. However, there are no intervention trials that 
show convincing evidence that treatment of such subtle thyroid dysfunction results in relief of 
symptoms. Therefore, national and international guidelines advise against prescribing thyroid 
hormone replacement therapy in patients with TSH levels within the normal range.
The results of this thesis did change my clinical practice in patients with persistent symptoms 
during treatment with thyroid hormone replacement therapy. Nowadays, I explain to patients 
that this is a common problem during treatment and that several factors may play a role. I 
discuss that thyroid hormone replacement therapy is perhaps not as optimal as natural secretion 
of thyroid hormones, strictly regulated by the hypothalamic-pituitary-thyroid axis with an 
individual set-point with a small margin. Subsequently, I would try to find the individual optimal 
TSH level (within the normal range) for the patient, titrating according to the symptoms, taking 
into account the characteristics of the patient. In addition, I now discuss with patients the 
fact that fatigue and mild thyroid dysfunction frequently are both present in patients without 
any causal relationship and if indicated I consider further diagnostic investigations or other 
treatment options (like cognitive behavior therapy or a rehabilitation program). 
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Conclusion
In conclusion, the results of this thesis show that subtle differences of thyroid function within 
the normal range are associated with short-term effects (symptoms) and long-term effects 
(mortality) and that mild iodine deficiency in the past can affect thyroid function at present. 
The results of this thesis do not support the suggestion of changing the limits of the reference 
range of serum TSH. Within the normal range, there seems to be a different optimal serum TSH 
level for each symptom and medical condition. This optimal serum TSH level may differ between 
populations with different patient characteristics, like age or iodine status. A clinician can take 
this into account when aiming for the optimal level of serum TSH during thyroid hormone 
replacement therapy.
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Chapter 1 provides an overview of the function of thyroid hormones, the effects of thyroid 
dysfunction, the importance of an adequate iodine intake and the effects of iodine deficiency. 
The aim of this thesis is to investigate short and long term effects of subtle differences in 
thyroid function and iodine status in the general population. The studies presented in this thesis 
are introduced. 
In Chapter 2, a study investigating the association between thyroid function within the normal 
range and fatigue is presented. A total of 5897 participants of the Nijmegen Biomedical Study 
filled out a questionnaire and serum thyroid stimulating hormone (TSH) and free thyroxine (FT
4
) 
were measured. Fatigue was evaluated by the RAND-36 vitality subscale and the Shortened 
Fatigue Questionnaire (SFQ). Euthyroid subjects with a serum TSH level of 0.4-1.0 mIU/L had a 
lower RAND-36 vitality score (65.2 vs. 66.8; regression coefficient (RC) -1.6, 95% confidence 
interval (CI) -2.6 to -0.5) and a higher SFQ score (11.7 vs. 11.0; RC 0.6, 95% CI 0.2-1.0) than 
those with a TSH of 1.0-2.0 mIU/L. Those with a serum FT
4
 of 18.5-22 pmol/L reported fatigue 
more often (52.5% vs. 33.3%; RR 1.4, 95% CI 1.0-1.9), had a lower RAND-36 vitality score 
(61.7 vs. 66.6; RC -4.4, 95% CI -8.1 to -0.6) and a higher SFQ score (13.2 vs. 11.0; RC 1.9, 
95% CI 0.4-3.3) than subjects with a FT
4
 level of 11.5-15 pmol/L. In comparison to euthyroid 
subjects without known thyroid disease, euthyroid subjects with previously known thyroid 
disease reported fatigue more often (52.3% vs. 34.0%; relative risk (RR) 1.3, 95% CI 1.0-1.5), 
had a lower RAND-36 vitality score (61.4 vs. 66.3; RC -2.9, 95% CI -5.3 to -0.6) and a higher 
SFQ score (13.7 vs. 11.1; RC 1.4, 95% CI 0.5-2.3). We concluded that within the normal range 
of serum TSH and FT
4
, fatigue seemed more severe in subjects with low-normal TSH levels and 
high-normal FT
4 
levels than middle-normal TSH and FT
4
 levels, although the effect was small. 
Subjects with a history of thyroid disease, but with normal serum TSH and FT
4
 concentrations, 
experienced more fatigue than the general population. 
Chapter 3 describes a study investigating whether thyroid function and thyroid peroxidase 
antibodies (TPOAb) are associated with depression, when using both state and trait parameters 
of depression. In 1125 participants of the Nijmegen Biomedical Study serum TSH, FT
4
 and 
TPOAb were measured twice. The Beck Depression Inventory 1A (BDI), a self-reported lifetime 
diagnosis of depression and the neuroticism scale of the Eysenck Personality Questionnaire 
Revised Short Scale (EPQ-RSS) were used to evaluate the presence of state and trait features 
of depression. We found no association between serum TSH and FT
4
 levels and BDI score, 
current depression, lifetime diagnosis of depression and EPQ-RSS neuroticism score. Subjects 
with TPOAb had higher EPQ-RSS neuroticism scores in comparison to subjects without TPOAb, 
mean score 4.1 versus 3.2 (RC 0.70, 95% CI 0.1-1.3). The prevalence of a lifetime diagnosis 
of depression was higher in subjects with positive TPOAb in comparison to participants 
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without TPOAb: 24.2% versus 16.7% (RR 1.4, 95% CI 1.0-2.1). We concluded that there 
was no association between thyroid function and depression. However, TPOAb were positively 
associated with trait markers of depression. The presence of TPOAb may be a vulnerability 
marker for depression. 
Chapter 4 reports a study investigating the influence of age on the relationship between 
thyroid function and mortality. In 5816 participants of the Nijmegen Biomedical Study without 
previously known thyroid disease, serum TSH, FT
4
 and TPOAb were measured in 2002-2003. 
The number of deaths was established in 2012 (median follow up time 9.4 years). Subclinical 
thyrotoxicosis was associated with mortality in subjects aged <65 years (hazard ratio (HR) 2.5, 
95% CI 1.1-5.7), but not in subjects aged >65 years. As for thyroid function within the normal 
range: in the 493 participants aged 80 years or older, a serum FT
4
 level in the high-normal range 
(18.5-22  pmol/l) was associated with a higher mortality in comparison with FT
4
 levels in the 
middle range (11.5-15.0 pmol/l): HR 1.7 (95% CI 1.0-2.9). In these elderly, TSH levels within the 
high-normal range (3.0-4.0  mIU/l) were also associated with a higher mortality in comparison 
with TSH levels within the middle range (1.0-2.0  mIU/l): HR 1.8 (95% CI 1.0-3.1). In summary, 
we demonstrated that the relationship between thyroid function and mortality differs according 
to age. This finding might (partially) explain the discrepant results of previous studies examining 
the relationship between thyroid function and mortality in different age groups.
In Chapter 5 we examined the within-individual variability of serum TSH and FT
4
 measurements 
several years apart in different study cohorts and we determined the magnitude of the 
underestimation of the association between thyroid function and disease rates in population-
based studies using only one baseline measurement. Due to regression dilution bias, variation 
in thyroid function can blur the association between thyroid function and the outcomes of 
interest. We used a pair of measurements of serum TSH and FT
4
 levels of subjects of the 
Nijmegen Biomedical Study (NBS) and the Rotterdam Study (RS) to calculate the regression 
dilution ratio (RDR) with a nonparametric method, the MacMahon’s method. Risk estimates 
could be corrected for regression dilution bias by dividing them by the RDR. The RDRs of serum 
TSH in the NBS and RS were 0.74 and 0.78, respectively. The RDRs of serum TSH were similar 
for women and men. The RDR of serum FT
4
 in subjects in the NBS was 0.77. We concluded that 
the relationship between thyroid function and disease rates is underestimated by studies using 
only one measurement of TSH and FT
4
. The true association will be about 33% (1/0.75) higher 
for studies with a follow-up time of 2-4 years.
In Chapter 6 a longitudinal study is presented, investigating whether the decrease of serum 
TSH and the increase of serum FT
4 
with age, previously found in a cross sectional survey in a 
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previously iodine deficient area, is an ongoing process apparent also in longitudinal analyses 
and whether it reflects an actual iodine deficiency or an iodine deficiency in the past. In 
980 participants of the Nijmegen Biomedical Study, we measured serum TSH, FT
4
, total T
3
, 
peroxidase antibodies and the urine iodine and creatinine concentration 4 years after our initial 
survey of thyroid function in which we reported a negative association between serum TSH 
and age. Within 4 years, serum TSH decreased with 5.4% (95% CI 2,5%-8,3%) and serum 
FT
4
 increased with 3.7% (95% CI 2.9%-4.6%). The median urinary iodine concentration of 
the population was 130 µg/L. The estimated 24-hour iodine excretion was not associated 
with serum TSH, T
3
, change of TSH or FT
4
 over time or with the presence of TPOAb. Only FT
4
 
appeared to be somewhat higher at lower urine iodine levels: a 1.01% (95% CI 0.17-1.84) 
higher FT
4
 for each lower iodine quintile. In conclusion, we found an ongoing decrease of 
serum TSH and increase of serum FT
4
 in a previously iodine insufficient population, despite 
the adequate iodine status at present. This suggests that low iodine intake at young age leads 
to thyroid autonomy (and a tendency to hyperthyroidism) that persists despite normal iodine 
intake later in life.
Chapter 7 reports a study, investigating whether there are current differences in the 
relationship between thyroid function and age in relation to differences in iodine intake in 
the past. Eight medical laboratories in several regions of the Netherlands, which are all iodine 
sufficient at present, but with a difference in iodine status in the past, provided the results of all 
serum TSH and FT
4
 measurements performed from 2006 until 2011, resulting in 330,802 TSH 
and 103,940 FT
4
 measurements. The negative association between TSH and age in elderly was 
only present in areas with a historically iodine deficiency (RC -0.008, 95% CI -0.009 to -0.007). 
In the historical iodine sufficient population, TSH showed no obvious increase or decrease with 
age. In both the historically iodine sufficient and deficient populations, serum FT
4
 levels were 
positively associated with age in elderly (RC 0.009, 95% CI 0.008-0.010 and RC 0.008, 95% 
CI 0.007-0.010 respectively). We therefore conclude that there are differences in relationship 
between thyroid function and age between populations with differences in iodine intake in the 
past, despite an adequate iodine status at present. 
Chapter 8 is a general discussion, that puts the main findings of this thesis in perspective. 
Additionally, a perspective on the reference values of serum TSH is given and the implications of 
the results of this thesis on clinical practice are discussed. Finally, recommendations for future 
research are made. 
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Samenvatting
Hoofdstuk 1 geeft een overzicht van de werking van schildklierhormonen, de gevolgen van 
een gestoorde schildklierfunctie, het belang van een adequate jodiuminname en de gevolgen 
van jodiumdeficiëntie. Het doel van dit proefschrift is om de korte en lange termijn gevolgen 
van subtiele verschillen in schildklierfunctie en jodium status in de algemene bevolking te 
onderzoeken. De studies van dit proefschrift worden geïntroduceerd. 
In Hoofdstuk 2 beschrijven wij de associatie tussen schildklierfunctie en moeheid. In 2002-
2003 vulden 5.897 deelnemers van de Nijmegen Biomedische Studie een vragenlijst in en 
werd bij hen thyroid stimulerend hormoon (TSH) en vrij thyroxine (FT
4
) bepaald in het serum. 
Moeheid werd geëvalueerd door de subschaal vitaliteit van de RAND-36 en de Shortened 
Fatigue Questionnaire (SFQ). Euthyreote deelnemers met een serum TSH van 0.4-1.0 mE/L 
hadden een lagere RAND-36 vitaliteitsscore (65.2 vs. 66.8; regressie coëfficiënt (RC) -1.6, 
95% confidence interval (CI) -2.6 tot -0.5) en een hogere SFQ score (11.7 vs. 11.0; RC 0.6, 
95% CI 0.2-1.0) dan de deelnemers met een serum TSH van 1.0-2.0 mE/L. Deelnemers met 
een serum FT
4
 tussen 18.5-22.0 pmol/L gaven vaker aan vermoeid te zijn (52.5% vs. 33.3%; 
relatieve risico (RR) 1.4, 95% CI 1.0-1.9), hadden een lagere RAND-36 vitaliteitsscore (61.7 
vs. 66.6; RC -4.4, 95% CI -8.1 tot -0.6) en een hogere SFQ score (13.2 vs. 11.0; RC 1.9, 
95% CI 0.4-3.3) dan mensen met een serum FT
4
 tussen 11.5-15.0 pmol/L. Mensen met een 
schildklieraandoening in de voorgeschiedenis maar momenteel een normaal serum TSH en FT
4
 
rapporteerden vaker vermoeidheid (52.3% vs. 34.0%; RR 1.3, 95% CI 1.0-1.5), hadden een 
lagere RAND-36 vitaliteitsscore (61.4 vs. 66.3; RC -2.9, 95% CI -5.3 tot -0.6) en een hogere SFQ 
score (13.7 vs. 11.1; RC 1.4, 95% CI 0.5-2.3) in vergelijking met euthyreote mensen zonder 
schildklieraandoening. Wij concludeerden dat binnen het normale gebied van serum TSH en 
FT
4
, moeheid ernstiger was bij mensen met een hoog-normale schildklierfunctie in vergelijking 
met mensen met een schildklierfunctie in het middelste deel van het normale gebied. Mensen 
met een schildklieraandoening in de voorgeschiedenis, maar met momenteel normale serum 
TSH en FT
4
 waarden, rapporteerden meer moeheid dan mensen zonder schildklieraandoening. 
In Hoofdstuk 3 beschrijven wij de resultaten van de studie waarbij onderzocht werd of de 
schildklierfunctie en de aanwezigheid van anti-TPO antistoffen (TPOAb) geassocieerd zijn 
met depressie, gebruikmakend van zowel state als trait parameters van depressie. Bij 1.125 
deelnemers van de Nijmegen Biomedische Studie werden serum TSH, FT
4
 en TPOAb twee 
keer bepaald. De Beck Depression Inventory (BDI), de aanwezigheid van een depressie in de 
voorgeschiedenis en de neuroticisme schaal van de Eysenck Personality Questionnaire Revised 
Short Scale (EPQ-RSS) werden gebruikt om de state en trait kenmerken van depressie te 
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evalueren. Er werd geen associatie gevonden tussen de serum TSH en FT
4
 waarden en de BDI 
score, de aanwezigheid van een huidige depressie, het ooit doorgemaakt hebben van een 
depressie en de EPQ-RSS neuroticisme score. Mensen met TPOAb hadden een hogere EPQ-RSS 
neuroticisme score in vergelijking met mensen zonder TPOAb (gemiddelde score 4.1 versus 
3.2 (RC 0.70, 95% CI 0.1-1.3)). De prevalentie van een doorgemaakte depressie was hoger 
bij mensen met TPOAb dan bij mensen zonder TPOAb: 24.2% versus 16.7% (RR 1.4, 95% CI 
1.0-2.1). Samenvattend vonden wij geen associatie tussen schildklierfunctie en depressie. Wel 
is de aanwezigheid van TPOAb geassocieerd met trait parameters van depressie. Mogelijk is de 
aanwezigheid van TPOAb een marker voor kwetsbaarheid voor depressie. 
Hoofdstuk 4 rapporteert een studie die de invloed van leeftijd op de relatie tussen 
schildklierfunctie en mortaliteit onderzocht. Bij 5.816 deelnemers van de Nijmegen Biomedische 
Studie werden TSH, FT
4
 en TPOAb in serum gemeten in 2002-2003. Het aantal overledenen 
werd vastgesteld in 2012 (mediane follow up duur 9.4 jaar). Subklinische hyperthyreoidie was 
geassocieerd met mortaliteit bij mensen jonger dan 65 jaar (hazard ratio (HR) 2.5, 95% CI 1.1-
5.7), maar niet bij mensen ouder dan 65 jaar. Subklinische en manifeste hypothyreoidie waren 
niet geassocieerd met mortaliteit. Ten aanzien van de schildklierfunctie binnen het normale 
gebied werden de volgende resultaten gevonden: bij de 493 deelnemers die ouder waren 
dan 80 jaar was een hoog-normale serum FT
4
 waarde van 18.5-22.0 pmol/L geassocieerd met 
een hogere mortaliteit in vergelijking met een serum FT
4
 waarde van 11.5-15.0 pmol/L: HR 
1.7 (95% CI 1.0-2.9). Bij ouderen waren ook hoog-normale serum TSH waarden van 3.0-4.0 
mE/L geassocieerd met mortaliteit in vergelijking met serum TSH waarden van 1.0-2.0 mE/L: 
HR 1.8 (95% CI 1.0-3.1). Deze associaties werden niet bij jongeren gevonden. Samenvattend 
laat deze studie dus zien dat de relatie tussen schildklierfunctie en mortaliteit verschilt tussen 
verschillende leeftijdscategorieën. Deze bevinding zou een verklaring kunnen zijn voor de 
discrepante resultaten van de voorgaande onderzoeken die de relatie tussen schildklierfunctie 
en mortaliteit beschrijven waarbij verschillende populaties met verschillende leeftijdscategorieën 
zijn onderzocht. 
Hoofdstuk 5 vermeldt een onderzoek waarin de intra-individuele variabiliteit van serum 
TSH en FT
4
 werd onderzocht en de mate waarin de associatie tussen schildklierfunctie en 
symptomen, aandoeningen of mortaliteit daardoor onderschat wordt. Ten gevolge van de 
regression dilution bias kan variatie in schildklierfunctie de associatie tussen schildklierfunctie 
en gezondheidsgerelateerde uitkomsten afzwakken. Serum TSH en FT
4
 werden enkele jaren 
na elkaar gemeten in twee verschillende studie cohorten, de Nijmegen Biomedische Studie 
en de Rotterdam Studie. Hiermee werd de regression dilution ratio (RDR) berekend met een 
nonparametrische methode, de MacMahon methode. Uitkomstmaten van associaties kunnen 
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worden gecorrigeerd voor de regression dilution bias door de uitkomstmaat te delen door 
de RDR. De RDRs van serum TSH in de Nijmegen Biomedische Studie en de Rotterdam Studie 
waren respectievelijk 0.74 en 0.78. De RDRs van TSH waren vergelijkbaar voor mannen en 
vrouwen. De RDR van serum FT
4
 van deelnemers van de Nijmegen Biomedische Studie was 
0.77. Wij concludeerden dat de relatie tussen schildklierfunctie en aandoeningen onderschat 
wordt door studies die slechts één meting van TSH en FT
4
 gebruiken. De daadwerkelijk 
associatie zal ongeveer met 33% (1/0.75) sterker zijn in studies met een follow up duur van 
twee tot vier jaar. 
In Hoofdstuk 6 wordt een studie gepresenteerd, waarbij werd onderzocht of de daling van 
serum TSH en de stijging van serum FT
4
 met de leeftijd, eerder aangetoond in een cross-
sectionele studie in een gebied met in het verleden een jodiumtekort, een doorlopend proces 
is dat ook te zien is bij longitudinale analyse. Daarnaast werd bekeken of dit veroorzaakt 
wordt door een huidig jodiumtekort. In 2002-2003 werden bij deelnemers van de Nijmegen 
Biomedische Studie serum TSH en FT
4
 bepaald. In 2006-2007 werden bij 980 van deze 
deelnemers nogmaals het serum TSH en FT
4
 gemeten, aangevuld met serum T
3
 en TPOAb 
en werden de urine jodium en kreatinine concentraties gemeten. In deze vier jaar daalde het 
gemiddelde serum TSH met 5.4% (95% CI 2,5%-8,3%) en steeg het FT
4
 met 3.7% (95% 
CI 2.9%-4.6%). De mediane urine jodium concentratie van de populatie was 130 µg/L. De 
geschatte 24-uurs jodium uitscheiding was niet geassocieerd met serum TSH, T
3
, verandering 
van TSH of FT
4
 in de vier jaar of met de aanwezigheid van TPOAb. Alleen het serum FT
4
 
was hoger bij mensen met een lagere jodiumuitscheiding: een lager jodium quintiel was 
geassocieerd met een 1.01% hogere serum FT
4
 waarde. Concluderend vonden wij in deze 
longitudinale studie een voortgaande daling van serum TSH en stijging van serum FT
4
 in een 
populatie met in het verleden een jodiumdeficiëntie, ondanks een adequate jodium inname op 
dit moment. Deze resultaten suggereren dat een lage jodium inname op jonge leeftijd leidt tot 
autonomie van de schildklier met een neiging tot hyperthyreoidie, die persisteert ondanks een 
normale jodium intake op latere leeftijd.      
In Hoofdstuk 7 beschrijven wij de verschillen in de relatie tussen schildklierfunctie en leeftijd 
in populaties met een verschil in jodium inname in het verleden maar met momenteel een 
adequate jodium inname. Acht laboratoria in verschillende regio’s in Nederland leverden de 
resultaten van alle serum TSH en FT
4
 metingen, aangevraagd door huisartsen, verricht van 2006 
tot 2011. Dit resulteerde in 330.802 TSH en 103.940 FT
4
 metingen. De negatieve associatie 
tussen serum TSH en leeftijd bij ouderen is alleen aanwezig in gebieden met jodiumdeficiëntie 
in het verleden (RC -0.008, 95% CI -0.009 tot -0.007). In de populatie met adequate 
jodiuminname in het verleden werd geen toename of afname van serum TSH met de leeftijd 
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gevonden. In zowel de historisch jodiumdeficiënte populatie als de historisch jodiumsufficiënte 
populatie werd een positieve associatie tussen serum FT
4
 en leeftijd gevonden bij ouderen 
(RC 0.009, 95% CI 0.008-0.010 and RC 0.008, 95% CI 0.007-0.010 respectievelijk). Wij 
concludeerden dat er verschillen zijn in de relatie tussen schildklierfunctie en leeftijd tussen 
populaties met een verschillende jodiuminname in het verleden, ondanks een huidige adequate 
jodium inname. 
Hoofdstuk 8 is een algemene discussie, waarbij de resultaten van dit proefschrift in perspectief 
worden geplaatst. Daarnaast beschrijven wij onze visie over de op dit moment gehanteerde 
normaal waarden van serum TSH. Tevens worden de implicaties van de resultaten van dit 
proefschrift voor de klinische praktijk besproken. Tenslotte worden er aanbevelingen gedaan 
voor toekomstig onderzoek.
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